<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Neuropharmacol</journal-id><journal-id journal-id-type="publisher-id">CN</journal-id><journal-title>Current Neuropharmacology</journal-title><issn pub-type="ppub">1570-159X</issn><issn pub-type="epub">1875-6190</issn><publisher><publisher-name>Bentham Science Publishers Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19305743</article-id><article-id pub-id-type="pmc">2644494</article-id><article-id pub-id-type="publisher-id">CN-5-268</article-id><article-id pub-id-type="doi">10.2174/157015907782793612</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Endocannabinoid Signaling in Midbrain Dopamine Neurons: More than Physiology?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Melis</surname><given-names>M</given-names></name><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Pistis</surname><given-names>P</given-names></name><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="aff1"><label/>B.B. Brodie Department of Neuroscience and Center of Excellence for the Neurobiology of Addiction, University of Cagliari, Monserrato (CA), 09042, Italy</aff><author-notes><corresp id="cor1"><label>*</label>Address correspondence to these authors at B.B. Brodie Department of Neuroscience, University of Cagliari, Cittadella Universitaria di Monserrato, 09042 Monserrato (CA), Italy; Tel: +39070675 4324/4340; Fax: +39070675 4320; E-mail: <email xlink:href="mpistis@unica.it / myriam@unica.it">mpistis@unica.it / myriam@unica.it</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2007</year></pub-date><volume>5</volume><issue>4</issue><fpage>268</fpage><lpage>277</lpage><history><date date-type="received"><day>13</day><month>2</month><year>2006</year></date><date date-type="rev-recd"><day>30</day><month>3</month><year>2007</year></date><date date-type="accepted"><day>3</day><month>4</month><year>2007</year></date></history><permissions><copyright-statement>&#x000a9;2007 Bentham Science Publishers Ltd.</copyright-statement><copyright-year>2007</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by/2.5/">http://creativecommons.org/licenses/by/2.5/</uri>) which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>Different classes of neurons in the CNS utilize endogenous cannabinoids as retrograde messengers to shape afferent activity in a short- and long-lasting fashion. Transient suppression of excitation and inhibition as well as long-term depression or potentiation in many brain regions require endocannabinoids to be released by the postsynaptic neurons and activate presynaptic CB1 receptors. Memory consolidation and/or extinction and habit forming have been suggested as the potential behavioral consequences of endocannabinoid-mediated synaptic modulation. </p><p>However, endocannabinoids have a dual role: beyond a physiological modulation of synaptic functions, they have been demonstrated to participate in the mechanisms of neuronal protection under circumstances involving excessive excitatory drive, glutamate excitotoxicity, hypoxia-ischemia, which are key features of several neurodegenerative disorders. </p><p>In this framework, the recent discovery that the endocannabinoid 2-arachidonoyl-glycerol is released by midbrain dopaminergic neurons, under both physiological synaptic activity to modulate afferent inputs and pathological conditions such as ischemia, is particularly interesting for the possible implication of these molecules in brain functions and dysfunctions. </p><p>Since dopamine dysfunctions underlie diverse neuropsychiatric disorders including schizophrenia, psychoses, and drug addiction, the importance of better understanding the correlation between an unbalanced endocannabinoid signal and the dopamine system is even greater. Additionally, we will review the evidence of the involvement of the endocannabinoid system in the pathogenesis of Parkinson&#x02019;s disease, where neuroprotective actions of cannabinoid-acting compounds may prove beneficial.</p><p>The modulation of the endocannabinoid system by pharmacological agents is a valuable target in protection of dopamine neurons against functional abnormalities as well as against their neurodegeneration.</p></abstract><kwd-group><title>Key Words</title><kwd>Dopamine</kwd><kwd>endocannabinoid</kwd><kwd>synaptic plasticity</kwd><kwd>neuroprotection</kwd><kwd>reward</kwd><kwd>schizophrenia</kwd><kwd>Parkinson,s disease.</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>In the last 15 years, the discovery and molecular dissection of the endocannabinoid (eCB) system has opened a new avenue in neuropsychopharmacological research. The interest in this system was further fuelled by the characterization of the dual nature of its actions within the central nervous system: modulation of synaptic functions and neuroprotection. In fact, endogenous cannabinoids (endocannabinoids) were discovered to play a role in the regulation of behavioural functions, such as reward and addiction, anxiety, feeding, and in the pathophysiological mechanisms of several neurodegenerative diseases. In this review, we will focus on the interaction between endocannabinoids (eCBs) and midbrain dopamine (DA) neurons, as recent studies highlight that it spans from the fine regulation of synaptic inputs to neuroprotection/neurorescue mecha-nisms, which may bear relevance in several neuropsychiatric disorders involving primarily dysfunctions of the DA neurons.</p></sec><sec><title>THE ENDOCANNABINOID SYSTEM</title><p>The eCBs are a family of lipid molecules that form a novel class of intercellular messengers, whose functions include retrograde signaling in the brain by modulating and/or mediating several types of synaptic plasticity. These molecules make up their own system (i.e. the endocannabinoid system) comprising synthesizing and inactivating enzymes, a transport protein, and the cannabinoid (CB) receptors [<xref ref-type="bibr" rid="R94">94</xref>,<xref ref-type="bibr" rid="R130"> 130</xref>]. </p><p>Among diverse endogenous lipid molecules with eCB-like activity, the best characterized eCBs &#x02013; in terms of biosynthesis, cellular transport, metabolism, and biologicalfunctions- are anandamide (AEA) [<xref ref-type="bibr" rid="R44">44</xref>] and 2-arachidonoyl glycerol (2-AG) [<xref ref-type="bibr" rid="R133">133</xref>,<xref ref-type="bibr" rid="R195"> 195</xref>], whose content is greatly elevated in response to a variety of physiological and/or pathological stimuli. Among the other eCBs, 2-arachidonyl-glyceryl ether (2-AGE, nolandin), <italic>O</italic>-arachidonoyl-ethanolamine (virodhamine), and <italic>N</italic>-arachidonoyl-dopamine (NADA) are the most investigated, although their physiological role is still unknown.</p><p>The increased levels of eCBs are usually part of an <italic>on demand</italic> response. In particular, the eCBs 2-AG and AEA have been shown to be synthesized <italic>on demand</italic> [<xref ref-type="bibr" rid="R18">18</xref>,<xref ref-type="bibr" rid="R46"> 46</xref>] by the postsynaptic cell in response to either physiological and/or pathological stimuli in several brain regions. Once released, they activate CB type 1 (CB1) receptors located presynaptically, and inhibit neurotransmitter release. As a result of their highly selective reduction of synaptic inputs onto the releasing neuron(s), eCBs influence both short- and long-term forms of synaptic plasticity.</p><p>Once activated CB1 receptors, eCBs are rapidly cleared away from their extracellular targets by a specific uptake system [<xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R87"> 87</xref>], named AEA membrane transporter (AMT), which is widely distri-buted throughout the brain [<xref ref-type="bibr" rid="R71">71</xref>]. Then AEA and 2-AG are degraded by two well-characterized enzymes, the fatty acid amide hydrolase (FAAH) and the monoacylglycerol (MAG) lipase, respectively [<xref ref-type="bibr" rid="R36">36</xref>,<xref ref-type="bibr" rid="R49"> 49</xref>,<xref ref-type="bibr" rid="R196"> 196</xref>,<xref ref-type="bibr" rid="R201"> 201</xref>]. </p><p>These peculiar features (i.e. <italic>on demand</italic> synthesis and rapid degradation) indicate that eCBs operate close to where they are synthesized, and make them as key molecules in brain functions and dysfunctions. </p><p>New pharmacological tools haveenabled the study of the physiological roles played by eCBs, opening up new strategies in the treatment of pain,obesity, and neurological diseases like multiple sclerosis,emotional disturbances such as anxiety and other psychiatricdisorders including drug addiction. More recently, pharmaceutical research aims to develop drugs exploiting the different biological mechanisms involved in the metabolic pathways of the two best characterized eCBs, AEA and 2-AG, to treat diverse disorders [<xref ref-type="bibr" rid="R153">153</xref>]. </p><p>In fact, AEA derives from the cleavage of a <italic>N</italic>-arachidonoyl-phosphatidylethanolamine (NAPE), a precursorsynthesized by the enzyme <italic>N</italic>-acyltransferase (NAT), whichrequiresthe presence of Ca<sup>2+</sup> and is regulated by cAMP [<xref ref-type="bibr" rid="R18">18</xref>,<xref ref-type="bibr" rid="R156"> 156</xref>]. Its release is catalyzedby a recently cloned specific phospholipase D (PLD) [<xref ref-type="bibr" rid="R83">83</xref>,<xref ref-type="bibr" rid="R147"> 147</xref>], whose activity is regulated by depolarizationand/or activation of iono-tropic (e.g. NMDA, nicotinic &#x003b1;7 neuronal receptors; [<xref ref-type="bibr" rid="R156">156</xref>,<xref ref-type="bibr" rid="R193"> 193</xref>] or metabotropicreceptors [<xref ref-type="bibr" rid="R73">73</xref>,<xref ref-type="bibr" rid="R96"> 96</xref>,<xref ref-type="bibr" rid="R208"> 208</xref>].</p><p>On the other hand, 2-AG derives from the metabolism of triacylglycerols, through receptor-dependent activation of phosphatidylinositol-specific phospholipase A<sub>1</sub> (PLA<sub>1</sub>) and/or C (PLC) [<xref ref-type="bibr" rid="R196">196</xref>]. The current model, proposing that activation of metabotropic receptors coupled to the PLC and diacylglycerol (DAG) lipase pathway leads to 2-AG production [<xref ref-type="bibr" rid="R156">156</xref>,<xref ref-type="bibr" rid="R194"> 194</xref>], is substantiated by both the cloning of the enzyme 1,2-DAG lipase [<xref ref-type="bibr" rid="R11">11</xref>] and the contribution of ionotropic purinergic receptors (e.g. P2XT; [<xref ref-type="bibr" rid="R217">217</xref>]) to 2-AG formation. </p><p>Irrespective of their different <italic>routes</italic>, binding properties and intrinsic activity at CB receptors [<xref ref-type="bibr" rid="R86">86</xref>,<xref ref-type="bibr" rid="R88"> 88</xref>,<xref ref-type="bibr" rid="R194"> 194</xref>], both AEA and 2-AG do activate CB receptors. The CB receptors are part of the superfamily of G protein-coupled receptors.The CB1 receptor is the most abundant G protein-coupled receptor expressed in the brain [<xref ref-type="bibr" rid="R84">84</xref>,<xref ref-type="bibr" rid="R90"> 90</xref>], but it is also found in diverse peripheral tissues (e.g. muscle, the gastrointestinal tract, liver, pancreas and adipose tissue) [<xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R43"> 43</xref>,<xref ref-type="bibr" rid="R84"> 84</xref>,<xref ref-type="bibr" rid="R90"> 90</xref>,<xref ref-type="bibr" rid="R213"> 213</xref>]. The CB2 receptor is instead found on several immune cells (e.g. monocytes, microglial cells, T- and B-cells), in the spleen and tonsils [<xref ref-type="bibr" rid="R59">59</xref>,<xref ref-type="bibr" rid="R144"> 144</xref>,<xref ref-type="bibr" rid="R156"> 156</xref>], and peripheral tissues [<xref ref-type="bibr" rid="R116">116</xref>]. In addition, increasing pharmacological evidence suggest the presence of CB2 receptors in the brain [<xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R148"> 148</xref>,<xref ref-type="bibr" rid="R206"> 206</xref>], as well as the existence of at least two non-CB1, non-CB2 receptors [<xref ref-type="bibr" rid="R82">82</xref>,<xref ref-type="bibr" rid="R89"> 89</xref>,<xref ref-type="bibr" rid="R103"> 103</xref>]. Lastly, pharmacological studies revealedthe existence of eCB targets other than CB receptors, including thetransient receptor potential vanilloid-1 (TRPV1) receptor [<xref ref-type="bibr" rid="R223">223</xref>].</p><p>Both CB1 and CB2 receptors are coupled to similar transduction systems. CB receptor activation was initially reported to inhibit cAMP formation through its coupling to G<sub>i </sub>proteins [<xref ref-type="bibr" rid="R43">43</xref>,<xref ref-type="bibr" rid="R91"> 91</xref>], resulting in a decrease of the protein kinase A-dependent phosphorylation processes as well. However, additional studies found that the CB receptors are also coupled to ion channels through the G<sub>olf</sub> protein, resulting in the inhibition of Ca<sup>2+</sup> influx through N- [<xref ref-type="bibr" rid="R117">117</xref>], P/Q- [<xref ref-type="bibr" rid="R200">200</xref>] and L- [<xref ref-type="bibr" rid="R65">65</xref>] type Ca<sup>2+</sup>channels, as well as the activation of inwardly rectifying potassium conductance and A currents [<xref ref-type="bibr" rid="R32">32</xref>,<xref ref-type="bibr" rid="R118"> 118</xref>]. Additionally, CB1 and CB2 receptors have been shown to be coupled to other intracellular cascades, including the mitogen-activated protein kinase cascade, the phosphatidylinositol 3-kinase, the focal adhesion kinase, ceramide signaling and nitric oxide production [<xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R42"> 42</xref>,<xref ref-type="bibr" rid="R62"> 62</xref>,<xref ref-type="bibr" rid="R88"> 88</xref>,<xref ref-type="bibr" rid="R142"> 142</xref>,<xref ref-type="bibr" rid="R171"> 171</xref>]. </p><p>The widespread presence of the eCBsystem correlates with its role as a relevant modulator of multiple physiological functions and not only in the CNS [<xref ref-type="bibr" rid="R45">45</xref>].A comprehensive analysis of all the functions of the eCBs is beyond the scope of the present review. The reader will find an extensive list of recent reviews that explore the physiological relevance of the eCB system elsewhere [<xref ref-type="bibr" rid="R99">99</xref>,<xref ref-type="bibr" rid="R153"> 153</xref>,<xref ref-type="bibr" rid="R165"> 165</xref>], whereas we focus on the cellular and system physiological events mediated by eCBs that are relevant to our understanding of their interplay with the DA system. </p><p>As we better describe below, in the midbrain 2-AG is the main eCB released <italic>on demand</italic> after cellular depolarization and/or receptor stimulation in a Ca<sup>2+</sup>-dependent manner. Once produced, it acts on CB1 receptors located on both presynaptic GABAergic and glutamatergic terminals. More generally, eCBs act similarly throughout the brain [<xref ref-type="bibr" rid="R156">156</xref>,<xref ref-type="bibr" rid="R177"> 177</xref>], with the end result of presynaptic inhibition of neurotransmitter release. </p><p>This phenomenon translates in different forms of short- and long-term synaptic plasticity, depending on the involvement of GABA or glutamate transmission, respectively. </p><p>eCBs, released upon depolarization and/or receptor activation, can transiently affect synaptic efficacy by suppressing either GABA or glutamate release, thus provoking depolarization-induced suppression of inhibition (DSI) or excitation (DSE), respectively [<xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R31"> 31</xref>,<xref ref-type="bibr" rid="R48"> 48</xref>,<xref ref-type="bibr" rid="R216"> 216</xref>]. eCBs can also affect other forms of short term synaptic transmission, which are induced by more physiologically relevant patterns of synaptic activity [<xref ref-type="bibr" rid="R15">15</xref>,<xref ref-type="bibr" rid="R17"> 17</xref>,<xref ref-type="bibr" rid="R136"> 136</xref>], and result in modulation of synaptic strength and/or firing pattern <italic>in vivo</italic> [<xref ref-type="bibr" rid="R10">10</xref>,<xref ref-type="bibr" rid="R29"> 29</xref>,<xref ref-type="bibr" rid="R136"> 136</xref>].</p><p>Additional forms of eCB modulation of synaptic transmission involve the induction of long-term synaptic plasticity, namely long-term potentiation (LTP) and depression (LTD). eCBs are strongly involved in the induction of LTD, whereas their role in LTP is probably indirect <italic>via</italic> heterosynaptic influences, as in the hippocampus [<xref ref-type="bibr" rid="R30">30</xref>], and perhaps in the prefrontal cortex [<xref ref-type="bibr" rid="R106">106</xref>]. Both these forms of synaptic plasticity involve changes in the strength of excitatory synapses that can last from minutes to several days [<xref ref-type="bibr" rid="R112">112</xref>]. Because changes in synaptic strength underlie changes in postsy-naptic receptor density, and ultimately in synapse remodeling, LTP and LTD are believed to play a critical role in memory consoli-dation and behavioural learning. Consequently, eCBs participate in the adjustment of synaptic strength [<xref ref-type="bibr" rid="R31">31</xref>,<xref ref-type="bibr" rid="R102"> 102</xref>,<xref ref-type="bibr" rid="R175"> 175</xref>]. Because activation of the eCB system affects not only synaptic remodelling [<xref ref-type="bibr" rid="R42">42</xref>,<xref ref-type="bibr" rid="R156"> 156</xref>], but also neuronal differentiation [<xref ref-type="bibr" rid="R172">172</xref>] and survival [<xref ref-type="bibr" rid="R128">128</xref>,<xref ref-type="bibr" rid="R152"> 152</xref>], eCBs guarantee not only a fine regulation of information processing,but also local protective mechanisms directed at preserving brain physiological function [<xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R27"> 27</xref>,<xref ref-type="bibr" rid="R51"> 51</xref>,<xref ref-type="bibr" rid="R95"> 95</xref>,<xref ref-type="bibr" rid="R97"> 97</xref>,<xref ref-type="bibr" rid="R128"> 128</xref>,<xref ref-type="bibr" rid="R131"> 131</xref>,<xref ref-type="bibr" rid="R137"> 137</xref>,<xref ref-type="bibr" rid="R143"> 143</xref>,<xref ref-type="bibr" rid="R185"> 185</xref>,<xref ref-type="bibr" rid="R186"> 186</xref>,<xref ref-type="bibr" rid="R209"> 209</xref>].</p></sec><sec><title>ENDOCANNABINOIDS AND DOPAMINE NEURONS: PHYSIOLOGY AND NEUROPROTECTION</title><p>A detailed description of the mesencephalic DA system is beyond the scope of this review. Here it suffices to say that DA neurons in the ventral tegmental area (VTA) are involved in the pathophysiology of psychiatric disorders and drug abuse. Their axons project to forebrain areas such as the nucleus accumbens (NAc) and the prefrontal cortex. A second major subdivision of mesencephalic DA neurons are those in the more lateral substantia nigra pars compacta (SNc), which project mainly to the striatum and are deeply interconnected to other nuclei in the basal ganglia circuits, being involved in the regulation of motor functions and in the pathogenesis of Parkinson&#x02019;s disease (PD).</p><p>The eCB system is emerging as an important modulator of the DA neurons. Neuronal activity of mesencephalic DA neurons is sensitive to exogenous cannabinoid agonists [<xref ref-type="bibr" rid="R57">57</xref>,<xref ref-type="bibr" rid="R70"> 70</xref>]. Both &#x00394;<sup> 9</sup>-tetrahydrocannabinol and synthetic CB1 receptor agonists dose-dependently enhance firing rate and burst activity of DA neurons in the VTA, whereas their effect on SNc neurons is weaker. Enhanced electrical activity results in an increase in DA release in terminal regions, such as the nucleus accumbens [<xref ref-type="bibr" rid="R25">25</xref>,<xref ref-type="bibr" rid="R198"> 198</xref>] and the prefrontal cortex [<xref ref-type="bibr" rid="R28">28</xref>,<xref ref-type="bibr" rid="R158"> 158</xref>]. Under this aspect, cannabinoids display effects similar to those of other drugs of abuse belonging to different classes, that were shown to enhance DA transmission with diverse mechanisms. The levels of CB1 receptors or mRNA in the VTA and in the SNc are very low or undetectable [<xref ref-type="bibr" rid="R84">84</xref>,<xref ref-type="bibr" rid="R132"> 132</xref>], thus a direct effect of cannabinoid agonists onto DA cells seems unlikely. However, several neuronal populations projecting to VTA or SNc DA neurons have been demonstrated to possess relatively large amounts of CB1 receptor mRNA, namely the glutamatergic neurons in the PFC and in the subthalamic nucleus, or the GABAergic neurons in the striatal complex as well as in the pars reticulata of the substantia nigra (SN) [<xref ref-type="bibr" rid="R129">129</xref>,<xref ref-type="bibr" rid="R132"> 132</xref>]. Thus, it is conceivable that low levels of CB1 receptors are located on glutamatergic and GABAergic terminals impinging on DA neurons [<xref ref-type="bibr" rid="R127">127</xref>,<xref ref-type="bibr" rid="R214"> 214</xref>], where they can fine-tune the release of inhibitory and excitatory neurotransmitter and regulate DA neuron firing.</p><p>Consistently, <italic>in vitro</italic> electrophysiological experiments from independent laboratories have provided evidence of CB1 receptor localization on glutamatergic and GABAergic axon terminals in the VTA and SNc. Perfusion of CB1 agonists depresses inhibitory and excitatory post-synaptic currents recorded from DA neurons [<xref ref-type="bibr" rid="R127">127</xref>,<xref ref-type="bibr" rid="R138"> 138</xref>,<xref ref-type="bibr" rid="R197"> 197</xref>]. This effect is apparently mediated by CB1 receptors located on presynaptic terminals, where they depress GABA and glutamate release onto DA cells. The presence of CB1 receptors strongly suggested a physiological role of eCBs in the modulation of synaptic functions.</p><p>This hypothesis was confirmed by patch-clamp experiments providing evidence that DA neurons release eCBs as retrograde messengers in a Ca<sup>2+</sup>-dependent manner. These messengers travel toward the presynaptic sites where modulate inputs by acting at CB1 receptors [<xref ref-type="bibr" rid="R136">136</xref>,<xref ref-type="bibr" rid="R161"> 161</xref>].</p><p>Under what circumstances DA neurons release eCBs? In general, a state of electrical activation is the prerequisite for the eCB release. Specifically, it is triggered by depolarization of the DA neuron [<xref ref-type="bibr" rid="R138">138</xref>], stimulation of excitatory afferents [<xref ref-type="bibr" rid="R136">136</xref>], induction of burst firing <italic>in vivo</italic> [<xref ref-type="bibr" rid="R136">136</xref>] and <italic>in vitro</italic> [<xref ref-type="bibr" rid="R161">161</xref>]. These stimuli induce a cascade of intracellular events ultimately leading to an increased intracellular Ca<sup>2+</sup> and release of eCBs. Under these circumstances, released eCBs transiently modulate presynaptically afferent activity and shape incoming inputs, thus inducing DSE or DSI [<xref ref-type="bibr" rid="R138">138</xref>,<xref ref-type="bibr" rid="R161"> 161</xref>,<xref ref-type="bibr" rid="R219"> 219</xref>]. The eCB 2-AG, and not AEA, is the most likely messenger in synaptic suppression in DA neurons, since the inhibition of its major synthesizing enzyme (i.e. the <italic>sn</italic>-1&#x02013;DAG lipase) abolishes suppression of excitation [<xref ref-type="bibr" rid="R136">136</xref>].</p><p>The characterization of the eCB system carried out in the VTA have not been replicated yet on the more lateral SNc, thus a comparison between these two important DA regions is not possible yet. Thus, we do not currently know whether the mechanisms mentioned above are common to the whole midbrain DA neuronal population. In principle, any generalization can be misleading, since SNc DA neurons possess specific intrinsic and synaptic properties, different in many instances from those in the VTA population. In the SNc, studies demonstrated the presence of high levels of AEA and detectable levels of the putative endocannabinoid NADA [<xref ref-type="bibr" rid="R127">127</xref>]. Besides their agonist properties at CB1 receptors, both AEA and NADA can be considered as endovanilloids, since they also activate TRPV1 receptors at physiological concentrations, whereas 2-AG activates only CB receptors. No information is yet available on 2-AG levels specifically in the SN, which would be of interest especially when compared to those found in the VTA. In slices containing the whole mesencephalon, 2-AG concentration is ten times higher than that of AEA [<xref ref-type="bibr" rid="R137">137</xref>]. Although an unknown proportion of the 2-AG detected in brain tissues could be of metabolic origin, it is likely that this eCB plays a major role in synaptic modulation of SNc DA neurons. Activation of CB1 or TRPV1 receptors in the SN exerts opposing actions on synaptic afferent to DA neurons, CB1 receptors inhibit glutamate and GABA release, whereas TRPV1 receptors potentiate excitatory transmission, possibly by depolarization of axon terminals and Ca<sup>2+</sup> entry [<xref ref-type="bibr" rid="R127">127</xref>]. Thus, a complex picture is emerging, where eCBs and endovanilloids finely tune DA neuron activity in the SN, but their contribution to the mechanisms of short-term synaptic plasticity has not yet been investigated. It is hoped that future studies will address this issue, since this is a significant gap in the research on the interaction between the dopaminergic and endocannabinoid systems, for its relevance in the control of motor activity, and in the neuropathology of PD (see below) and other movement disorders.</p></sec><sec><title>FUNCTIONAL CONSEQUENCES OF ENDOCANNABINOID SIGNALING IN DA NEURONS</title><p>DA neurons fire <italic>in vivo</italic> in two main different patterns of activity: regular pace-maker-like activity and burst firing [<xref ref-type="bibr" rid="R75">75</xref>], the latter is associated to transient increases in DA release in the nucleus accumbens [<xref ref-type="bibr" rid="R74">74</xref>]. By using techniques with good temporal resolution (e.g. fast-scan cyclic voltammetry) it was demonstrated that burst firing is more efficacious to evoke DA release as compared to regular firing, when the average frequency was the same [<xref ref-type="bibr" rid="R74">74</xref>]. Thus, functional efficacy of DA neurons depends more on firing pattern (bursting <italic>vs</italic>. regular) then on the simple average firing frequency.</p><p>Firing rate and pattern of DA neurons depend on the activity of excitatory and inhibitory inputs (see [<xref ref-type="bibr" rid="R125">125</xref>] for a review and references therein), thus a feedback control of these inputs is crucial for normal functioning of DA neurons. An increase in glutamatergic transmission enhances DA neuronal activity and produces bursting pattern, which can be reproduced by local injection of glutamate [<xref ref-type="bibr" rid="R139">139</xref>,<xref ref-type="bibr" rid="R149"> 149</xref>,<xref ref-type="bibr" rid="R150"> 150</xref>]. GABAergic input is mostly from the striatal complex; it includes inputs from the NAc, the caudate nucleus, globus pallidus and ventral pallidum [<xref ref-type="bibr" rid="R77">77</xref>,<xref ref-type="bibr" rid="R189"> 189</xref>,<xref ref-type="bibr" rid="R190"> 190</xref>,<xref ref-type="bibr" rid="R215"> 215</xref>]. An important GABAergic input arises also from interneurons in the midbrain [<xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R81"> 81</xref>]. An increase in GABAergic drive reduces firing rate and decrease bursting, <italic>via</italic> both GABA<sub>A</sub> and GABA<sub>B</sub> receptors. Switching from regular to burst firing is triggered by behavioural stimuli: reward prediction error [<xref ref-type="bibr" rid="R179">179</xref>-<xref ref-type="bibr" rid="R182">182</xref>] or the identification of contextual and behavioural stimuli responsible for unpredicted events [<xref ref-type="bibr" rid="R160">160</xref>]. Thus, the finding that eCBs may be released during burst of DA neurons, similar to those caused by behaviourally salient events, appears particularly intriguing. These molecules may have a crucial role in setting and/or modulating signal-to-noise ratio of DA neuron activity, especially during emotional processing and sensory perception [<xref ref-type="bibr" rid="R107">107</xref>]. Indeed, cannabinoids strongly influence emotional processing and sensory perceptions and have been shown to perturb the emotional significance of sensory information [<xref ref-type="bibr" rid="R76">76</xref>,<xref ref-type="bibr" rid="R212"> 212</xref>]. </p><p>Disturbances of the eCB system, such as alterations in brain eCB levels or expression of CB1 receptors, induced by chronic cannabinoid intake [<xref ref-type="bibr" rid="R210">210</xref>] or of idiopathic origin, may be a pathophysiological substrate of neuropsychiatric disorder such as schizophrenia, and maintain or worsen their course [<xref ref-type="bibr" rid="R72">72</xref>,<xref ref-type="bibr" rid="R110"> 110</xref>,<xref ref-type="bibr" rid="R178"> 178</xref>]. Indeed, <italic>Cannabis</italic> use is frequent among psychotic patients [<xref ref-type="bibr" rid="R101">101</xref>], and there is little doubt that it may precipitate psychotic episodes and worsen the course of the disease [<xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R111"> 111</xref>], possibly due to its DA-releasing properties [<xref ref-type="bibr" rid="R211">211</xref>]. Additional evidence suggesting a link between cannabinoids and schizophrenia is that adolescent <italic>Cannabis</italic> consumption was associated with an higher incidence of schizophrenia in adulthood [<xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R22"> 22</xref>,<xref ref-type="bibr" rid="R220"> 220</xref>], when corrected for confounding variables. In fact, the DA system undergoes extensive maturation and rearrangement until early adulthood: for example, DA innervation of terminal areas, such as the prefrontal cortex is not completed until late adolescence in the rat [<xref ref-type="bibr" rid="R168">168</xref>]; a reduced basal levels of DA and a reduced pool of readily releasable DA have been reported in adolescent rats [<xref ref-type="bibr" rid="R192">192</xref>]; D<sub>1</sub> and D<sub>2</sub> receptor binding in the striatum undergoes robust changes during adolescence as a consequence of extensive pruning of DA synapses [<xref ref-type="bibr" rid="R199">199</xref>]. For these reasons, the DA system may be particularly vulnerable to exogenous cannabinoid-induced disruption of the eCB system [<xref ref-type="bibr" rid="R159">159</xref>].</p><p>Thus, a better understanding of this neuromodulatory system is crucial in the development of pharmacological tools as a potential therapy in psychotic disorders.</p></sec><sec><title>ENDOCANNABINOIDS AND NEUROPROTECTION OF DA NEURONS</title><p>Membrane depolarization or stimulation of excitatory afferents are among the better characterized mechanisms to trigger eCB release from postsynaptic neurons, including the DAergic ones. This evidence, among others, led researchers to expect that eCBs might possess neuroprotective actions [<xref ref-type="bibr" rid="R134">134</xref>]. In fact, either depolarization of neuronal membrane or excessively strong excitatory activity, often occurring simultaneously, can lead to or worsen neuronal damage. Neurodegeneration is the main cause of morbidity in several diseases such as Huntington&#x02019;s, Parkinson&#x02019;s, Alzheimer&#x02019;s, motor neuron disease and stroke. Although the pathways leading to neuronal death will be different in these disorders, some similarities are likely, such as glutamate-induced excitotoxicity and damage from reactive oxygen species and toxic ion imbalances. Neuronal damage caused by toxic or ischemic insults, such as energy or oxygen deprivation, as well as traumatic injury, is strongly dependent on the release of excitatory amino acids and on rise of intracellular Ca<sup>2+</sup>. By depressing the strength of excitation through eCBs, neurons might reduce potential excitotoxic damage. Consistently, mice lacking the CB1 receptor gene are more susceptible to injury after stroke [<xref ref-type="bibr" rid="R154">154</xref>] or kainic-induced epileptic seizures [<xref ref-type="bibr" rid="R128">128</xref>]. It has been suggested that the release of eCBs during neuronal injury might be a protective response. Accordingly, exogenous cannabinoids have been shown to exert neuroprotection in a variety of <italic>in vitro </italic>and <italic>in vivo </italic>models of neuronal injury [<xref ref-type="bibr" rid="R56">56</xref>]. Their effects occur <italic>via</italic> different mechanisms, such as prevention of excitotoxicity by CB1-mediated inhibition of glutamatergic transmission, reduction of Ca<sup>2+</sup> influx, and subsequent inhibition of deleterious cascades, TNF-alpha formation, and anti-oxidant activity [<xref ref-type="bibr" rid="R56">56</xref>].</p><p>The role of (endo)cannabinoids as potential neuroprotective agents in neurodegenerative diseases, of either purely genetic or multifactorial origin, has been strengthened by recent studies where changes in CB1 receptors, as well as in the levels of their endogenous ligands, have been described in animal models of PD [<xref ref-type="bibr" rid="R55">55</xref>] and human patients [<xref ref-type="bibr" rid="R157">157</xref>]. A growing body of evidence suggests that dramatic alterations of CB1 signalling occur in PD, and following levodopa treatment [<xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R55"> 55</xref>]. Some of these changes might reflect compensatory mechanisms involving the plasticity of the eCB system, whereas other changes may also contribute to the pathophysiology of parkinsonism motor disorders [<xref ref-type="bibr" rid="R16">16</xref>].</p><p>Since eCBs depress synaptic glutamate transmission [<xref ref-type="bibr" rid="R136">136</xref>,<xref ref-type="bibr" rid="R138"> 138</xref>] and limit further depolarization, their release can be envisaged as a protective mechanism by which DA neurons reduce the strength of incoming excitation. These cells are exquisitely vulnerable to excitotoxicity and oxidative stress, and this vulnerability might be partially correlated with or even be explained by the specific regulation of their excitability [<xref ref-type="bibr" rid="R100">100</xref>].</p><p>Studies in our laboratory provided evidence that eCBs released by DA neurons exert protective actions in a model of ischemia/reperfusion [<xref ref-type="bibr" rid="R137">137</xref>]. Perfusion of brain slices in oxygen and glucose deprivation for 7 minutes induced a progressive depolarization of DA neuron membrane and interruption of firing activity, which can be irreversible. The prediction that this depolarization would trigger the release of eCBs was confirmed by the finding that blockade of CB1 receptors induced a considerable worsening of the outcome of experimental ischemia [<xref ref-type="bibr" rid="R137">137</xref>]. Thus, eCBs might represent one of the neuroprotective mechanisms reducing DA neuronal damage during episodes of energy deprivation. The current hypothesis posits that activation of CB1 receptors by eCBs might depress glutamate release in the ischemic tissue, and consequently decrease Ca<sup>2+</sup> entry and the excitotoxic damage. In keeping with previous findings, 2-AG was demonstrated to be involved in the mechanisms of neuroprotection, since inhibition of its synthesis was detrimental.</p><p>Disturbances of the eCB system might be of considerable importance in the pathogenesis of neurological disorders involving the DA system. Accordingly, dysfunctional eCB signal has been reported in PD and other movement disorders [<xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R151"> 151</xref>,<xref ref-type="bibr" rid="R170"> 170</xref>,<xref ref-type="bibr" rid="R203"> 203</xref>]. A pharmacological intervention aimed at the enhancement of this signal might prove useful as neuroprotective therapy to reduce cell suffering/death in the early stages of these diseases. Particularly, inhibitors of MGL [<xref ref-type="bibr" rid="R122">122</xref>,<xref ref-type="bibr" rid="R174"> 174</xref>], or of the putative eCB membrane transporter [<xref ref-type="bibr" rid="R38">38</xref>], which would enhance endogenous 2-AG levels, might prove as valuable targets, and be therapeutically useful. It is also possible that exogenous cannabinoids might mimic the eCBs by acting as neuroprotective agents in neurodegenerative diseases. This hypothesis is based, among others, on the observation that cannabinoids protect neurons from toxic insults such as glutamatergic excitotoxicity [<xref ref-type="bibr" rid="R184">184</xref>], ischemic stroke [<xref ref-type="bibr" rid="R145">145</xref>], hypoxia [<xref ref-type="bibr" rid="R188">188</xref>], trauma [<xref ref-type="bibr" rid="R152">152</xref>], oxidative stress [<xref ref-type="bibr" rid="R128">128</xref>], ouabain-induced secondary excitotoxicity [<xref ref-type="bibr" rid="R204">204</xref>,<xref ref-type="bibr" rid="R205"> 205</xref>]. Most of these protective effects appear to be mediated by the activation of the CB1 receptors [<xref ref-type="bibr" rid="R154">154</xref>], although the contribution of other different mechanisms (i.e., antioxidant and/or anti-inflammatory properties) cannot be ruled out [<xref ref-type="bibr" rid="R78">78</xref>,<xref ref-type="bibr" rid="R79"> 79</xref>,<xref ref-type="bibr" rid="R89"> 89</xref>]. Cannabinoids were also shown to be neuroprotective in animal models of PD, mainly for their known antioxidant and CB1 receptor-independent properties [<xref ref-type="bibr" rid="R63">63</xref>,<xref ref-type="bibr" rid="R105"> 105</xref>], but an effect through activation of CB1 receptors cannot be excluded. We found that the CB1 agonist WIN55212 exerted neuroprotective actions on DA cells subjected to ischemia, but the protection was apparent at the lowest concentrations tested (1-10 nM), whereas higher concentrations (0.1-1 &#x003bc; M) were detrimental [<xref ref-type="bibr" rid="R137">137</xref>]. These results support the idea that CB1 receptor agonists exert biphasic effects, with low doses being the most effective. This narrow concentration-response curve might explain why other studies found exogenous cannabinoids, such as HU210, neurotoxic to mesencephalic DA neurons in culture at higher concentrations (1 &#x003bc;M) [<xref ref-type="bibr" rid="R98">98</xref>]. The reason for negative effect of moderate to high concentrations of CB1 agonists is not currently known. One possibility is that high concentrations of CB1 agonist may disrupt the balance between suppression of glutamate and GABA release, by favouring the latter and therefore reducing or reversing their neuroprotective actions. The study by Kim <italic>et al.</italic> (2005) found also that exogenously applied AEA was detrimental to the survival of DA neurons. However, neurotoxic actions of AEA were exerted through activation of TRPV1 receptors, where it acts as a weak agonist. This finding adds a further matter of complexity in the balance between neuropretective/neurotoxic action of (endo) cannabinoids, since it is expected that activation of TRPV1 receptor by mixed eCB/endovanilloid substances (such as anandamide and NADA) may promote cell death through Ca<sup>2+</sup> entry [<xref ref-type="bibr" rid="R98">98</xref>] and/or stimulation of glutamate release [<xref ref-type="bibr" rid="R127">127</xref>].</p></sec><sec><title>ENDOCANNABINOID SIGNALING IN REINFORCEMENT AND ADDICTION </title><p>The discovery that several lipid molecules with eCB-like activity are released by midbrain DA neurons (i.e. AEA, 2-AG, NADA; [<xref ref-type="bibr" rid="R126">126</xref>,<xref ref-type="bibr" rid="R127"> 127</xref>,<xref ref-type="bibr" rid="R136"> 136</xref>,<xref ref-type="bibr" rid="R137"> 137</xref>] has highlighted their role in modulating the reward pathway, and consequently opened new avenues in both understanding and treating drug addiction (for a recent review see [<xref ref-type="bibr" rid="R124">124</xref>]. In fact, the eCBs released by VTA DA neurons, by moving retrogradely toward presynaptic CB1 receptors located on both glutamatergic and GABAergic terminals [<xref ref-type="bibr" rid="R136">136</xref>,<xref ref-type="bibr" rid="R138"> 138</xref>,<xref ref-type="bibr" rid="R161"> 161</xref>,<xref ref-type="bibr" rid="R219"> 219</xref>], finely adjust the balance between excitatory and inhibitory synaptic inputs, thus contributing to the regulation of their own firing pattern and/or activity and, consequently, of the whole reward pathway. Since activation and inhibition of this circuit correlates with drug- seeking/taking behaviours and withdrawal/drug craving, respectively, the eCBs by affecting DA neuronal function might participate in these behaviours as well. In addition, the findings that eCBs release and CB1 receptor activation are necessary for LTD in both the nucleus accumbens [<xref ref-type="bibr" rid="R162">162</xref>,<xref ref-type="bibr" rid="R163"> 163</xref>] and the dorsal neostriatum [<xref ref-type="bibr" rid="R67">67</xref>-<xref ref-type="bibr" rid="R69">69</xref>] support their involvement in those behaviours mediating the crucial transition from the reward-dependent form of drug-taking to the compulsive one. This hypothesis is supported by the evidence that both pharmacological and genetic impairment of CB1 receptors inhibit motivated behaviours [<xref ref-type="bibr" rid="R33">33</xref>-<xref ref-type="bibr" rid="R35">35</xref>,<xref ref-type="bibr" rid="R39"> 39</xref>-<xref ref-type="bibr" rid="R41">41</xref>,<xref ref-type="bibr" rid="R52"> 52</xref>,<xref ref-type="bibr" rid="R53"> 53</xref>,<xref ref-type="bibr" rid="R108"> 108</xref>,<xref ref-type="bibr" rid="R109"> 109</xref>,<xref ref-type="bibr" rid="R123"> 123</xref>,<xref ref-type="bibr" rid="R146"> 146</xref>,<xref ref-type="bibr" rid="R176"> 176</xref>] as well as acquisition of natural rewards [<xref ref-type="bibr" rid="R166">166</xref>] and drug-induced increased DA neurotransmission [<xref ref-type="bibr" rid="R26">26</xref>,<xref ref-type="bibr" rid="R93"> 93</xref>,<xref ref-type="bibr" rid="R155"> 155</xref>]. Additionally, the finding that CB1 receptors might contribute to human vulnerability to addiction [<xref ref-type="bibr" rid="R221">221</xref>] clearly indicates that the eCB system is a crucial substrate in the neurobiology of drug addiction.</p><p>Many mechanisms of action have been proposed for the interactions between blockade of eCBs&#x02019; action and treatment of drug addiction [<xref ref-type="bibr" rid="R64">64</xref>,<xref ref-type="bibr" rid="R107"> 107</xref>,<xref ref-type="bibr" rid="R114"> 114</xref>,<xref ref-type="bibr" rid="R124"> 124</xref>], and they all over-emphasize the interplay between the DA and eCB and/or opioid systems. However, while the DA system appears to be involved more than others in the pathophysiology of addiction, the studies examining eCB actions in the reward pathway have not fully elucidated the mechanisms underlying their involvement in the several aspects of drug dependence (e.g.: eCBs released in the VTA and primary rewarding effects of diverse drugs of abuse; eCB role in relapse to drug-seeking behaviours). The most difficult part is, in fact, to interpret the observations regarding eCB actions in the VTA [<xref ref-type="bibr" rid="R136">136</xref>,<xref ref-type="bibr" rid="R138"> 138</xref>,<xref ref-type="bibr" rid="R161"> 161</xref>]. How can we explain their role in the rewarding properties of drugs of abuse, when they can simultaneously inhibit both GABAergic and glutamatergic synaptic inputs onto VTA DA neurons? One possibility is that eCBs released by VTA DA neurons might selectively regulate their own synaptic inputs depending upon the relative level of synaptic activation of the different pathways. Thus, one possible scenario might be that when cortical afferents to the VTA are activated, producing long-lastingadaptations in DA cells that contribute to the development and maintenance of behavioural sensitization and, therefore, to drug addiction [<xref ref-type="bibr" rid="R164">164</xref>,<xref ref-type="bibr" rid="R173"> 173</xref>,<xref ref-type="bibr" rid="R202"> 202</xref>,<xref ref-type="bibr" rid="R207"> 207</xref>,<xref ref-type="bibr" rid="R218"> 218</xref>], eCBs might selectively act on and dampen these glutamatergic inputs [<xref ref-type="bibr" rid="R136">136</xref>]. This intriguing scenario might explain eCB key role in the common neurobiological substrate of motivation and addiction, and suggest how CB1 receptor blockade has proven useful in the treatment of drug addiction. Hence, despite of the many and complex neurobiological mechanisms thought to be at the basis of drug addiction, it is noteworthy to stress the undeniable usefulness of CB1 receptor blockade as promising efficacious treatment of addiction to the diverse substances, irrespective of the mechanism of action. It is of particular interest, in fact, that pharmacological blockade of CB1 receptors with SR141716A (i.e. rimonabant) prevents reinstatement and/or relapse to drug-seeking behaviour [<xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R34"> 34</xref>,<xref ref-type="bibr" rid="R35"> 35</xref>,<xref ref-type="bibr" rid="R41"> 41</xref>,<xref ref-type="bibr" rid="R52"> 52</xref>,<xref ref-type="bibr" rid="R53"> 53</xref>,<xref ref-type="bibr" rid="R60"> 60</xref>] whereas positive modulation of CB1 receptors enhances the effects of sub-threshold doses of the same drugs [<xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R41"> 41</xref>,<xref ref-type="bibr" rid="R61"> 61</xref>,<xref ref-type="bibr" rid="R191"> 191</xref>]. Thus, it appears compelling, and promising as well, to develop pharmacological tools aimed at activating the eCB system in order to both prevent relapse to drug use and treat drug addiction.</p></sec><sec><title>ENDOCANNABINOIDS IN MOTOR COORDINATION AND PARKINSON'S DISEASE </title><p>The observations that synthetic cannabinoids, as well as hemp-derived ones, and eCBs have powerful inhibitory effects on motor activity [<xref ref-type="bibr" rid="R37">37</xref>,<xref ref-type="bibr" rid="R58"> 58</xref>,<xref ref-type="bibr" rid="R169"> 169</xref>], together with the discovery that both eCBs and CB1 receptors are abundantly distributed in the basal ganglia [<xref ref-type="bibr" rid="R47">47</xref>,<xref ref-type="bibr" rid="R84"> 84</xref>,<xref ref-type="bibr" rid="R85"> 85</xref>], strongly suggest that this system is involved in the regulation of motor behaviour as well as basal ganglia-related movement disorders, such as PD. </p><p>Beside the changes observed in CB1 receptors within the basal ganglia during normal aging [<xref ref-type="bibr" rid="R119">119</xref>,<xref ref-type="bibr" rid="R121"> 121</xref>,<xref ref-type="bibr" rid="R167"> 167</xref>], changes in these receptors in the postmortem basal ganglia of humans affected by PD have also been demonstrated [<xref ref-type="bibr" rid="R104">104</xref>]. Some of these changes are likely to reflect compensatory mechanisms by which plasticity in the eCB signaling might be invoked in, or contribute to the pathophysiology of parkinsonism motor complications [<xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R187"> 187</xref>]. Additionally, like many other neurological disorders, PD is accompanied by excitotoxicity, Ca<sup>2+</sup> imbalance, and oxidative stress that lead to progressive neuronal death [<xref ref-type="bibr" rid="R50">50</xref>,<xref ref-type="bibr" rid="R135"> 135</xref>]. As already mentioned above, SNc DA neurons are particularly exposed to oxidative stress because the metabolism of DA gives rise to several molecules that can act as endogenous toxins [<xref ref-type="bibr" rid="R113">113</xref>]. Thus, one plausible speculation is that -once released by these DA cells- eCBs might act not only as neuroprotective but also as neurorescue molecules to provide protection against the progression of neuronal injury characteristic of PD. However, it is still unknown whether a phenomenon similar to the one occurring in the VTA during energy deprivation [<xref ref-type="bibr" rid="R137">137</xref>] takes also place in the SNc. But if this is the case, the most likely scenario is that SNc DA cells would release eCBs to dampen the hyperactivated corticostriatal glutamatergic transmission, a feature of experimental models of PD [<xref ref-type="bibr" rid="R19">19</xref>,<xref ref-type="bibr" rid="R20"> 20</xref>,<xref ref-type="bibr" rid="R23"> 23</xref>,<xref ref-type="bibr" rid="R183"> 183</xref>]. Hence,AEAfound in SNc slices, which inhibits presynaptic glutamate release in this area [<xref ref-type="bibr" rid="R126">126</xref>] and the striatum as well [<xref ref-type="bibr" rid="R66">66</xref>,<xref ref-type="bibr" rid="R92"> 92</xref>], would act similarly to ionotropic glutamate receptors antagonists and improve symptoms of experimentalPD [<xref ref-type="bibr" rid="R24">24</xref>]. Accordingly, increased levels of AEA [<xref ref-type="bibr" rid="R47">47</xref>,<xref ref-type="bibr" rid="R54"> 54</xref>,<xref ref-type="bibr" rid="R80"> 80</xref>,<xref ref-type="bibr" rid="R115"> 115</xref>] together with a downregulation of AMT and FAAH have been found in an experimental model of PD [<xref ref-type="bibr" rid="R54">54</xref>,<xref ref-type="bibr" rid="R80"> 80</xref>,<xref ref-type="bibr" rid="R115"> 115</xref>], indicating that the eCB system undergoes complex plastic changes leading to/during PD. Altogether, the above mentioned findings allow to suggest that targeting specifically the enzyme FAAH (i.e. pharmacological inhibition) might prove beneficial/useful as a novel approach to treat the abnormalcorticostriatal glutamatergic activity observed inPD. Of particular interest is also that enhancement of protective eCB signaling can be achieved through a dual, although selective, pharmacologicalinhibition of the transporter and FAAH respectively [<xref ref-type="bibr" rid="R95">95</xref>]. Karianan <italic>et al.</italic>, in fact, indicate how disruption of the two distinct mechanisms of eCB inactivation, combining transport and FAAH inhibitors AM404 and AM374, causesadditive effects mediated by potentiation of eCB tone acting on CB1 receptors.Accordingly, by enhancing AEA availability, through inhibition of AMT and FAAH, most deficits (e.g. akinesia and sensorimotor orientation) were ameliorated in an experimental model of PD [<xref ref-type="bibr" rid="R54">54</xref>]. </p><p>Interestingly, levodopa treatment reverses the abnormalities of the eCB system in those experimental models of PD, where DA depletion is obtained by injecting either 6-OHDA or MPTP in the striatum [<xref ref-type="bibr" rid="R104">104</xref>,<xref ref-type="bibr" rid="R115"> 115</xref>,<xref ref-type="bibr" rid="R120"> 120</xref>,<xref ref-type="bibr" rid="R168"> 168</xref>]. Therefore, one might speculate that the eCB system is under negative control of DA transmission, and its involvement is part of an attempt to counteract the increased GABAergic signaling in the globus pallidus, another component of the unbalanced basal ganglia physiology contributing to PD symptoms [<xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R13"> 13</xref>,<xref ref-type="bibr" rid="R21"> 21</xref>]. In sharp contrast, a different model of PD (i.e. reserpine-induced PD), where 2-AG levels were found increased in the globus pallidus [<xref ref-type="bibr" rid="R47">47</xref>], suggested that enhanced eCBs levels in this area contribute to PD symptom generation instead, and that selective CB1 receptor blockade might be therapeutically useful. However, CB1 receptor blockade in non-human primates failed to alleviate PD symptoms [<xref ref-type="bibr" rid="R140">140</xref>,<xref ref-type="bibr" rid="R141"> 141</xref>]. It is worth mentioning that differences in the basal ganglia physiology between primates and rodents, and/or different models of experimental PD might account for opposing results found in literature.</p><p>Noteworthy, CB1 receptor stimulation exerts a biphasic effect not only on movement [<xref ref-type="bibr" rid="R222">222</xref>] but also on protection (see above). Therefore, it is important to keep in mind that a narrow &#x0201c;therapeutic window&#x0201d; might prove useful for treatment of PD symptoms, whether this is obtained by either enhancing eCB availability through inhibition of their uptake and/or hydrolysis or administering CB1 receptor agonists within the proper dose range.</p></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>In summary, accumulating evidence indicate that eCBs are important modulators of DA neuron functions. Dysfunctions of DA neurons lead to several very frequent invalidating diseases, such as schizophrenia or PD, which also still represent an unmet clinical need. It is therefore crucial to understand how the eCB system is involved in the normal physiological regulation of the DA system, as well as if it plays a role in the in the pathophysiological mechanisms of DA neurons&#x02019; diseases. Cannabinoids have unfavorable side effects that strongly limit their clinical usefulness. However, in recent years several compounds which modulate the eCB system, without directly activating CB1 receptors, have been developed. Preclinical studies indicated that they may possess a more favorable pharmacological profile, but their possible evaluation in clinical studies is still very distant. In future, studies are needed to better characterize the role of the eCB system in pathology, in particular their involvement in schizophrenia, or to resolve the controversial issue of neuroprotective <italic>vs</italic>. neurotoxic effect of exogenous or endogenous cannabinoids.</p></sec></body><back><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alger</surname><given-names>BE</given-names></name></person-group><article-title>Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids</article-title><source>Prog. Neurobiol.</source><year>2002</year><volume>68</volume><fpage>247</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">12498988</pub-id></citation></ref><ref id="R2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andreasson</surname><given-names>S</given-names></name><name><surname>Allebeck</surname><given-names>P</given-names></name><name><surname>Engstrom</surname><given-names>A</given-names></name><name><surname>Rydberg</surname><given-names>U</given-names></name></person-group><article-title>Cannabis and schizophrenia.A longitudinal study of Swedish conscripts</article-title><source>Lancet</source><year>1987</year><volume>2</volume><fpage>1483</fpage><lpage>1486</lpage><pub-id pub-id-type="pmid">2892048</pub-id></citation></ref><ref id="R3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anggadiredja</surname><given-names>K</given-names></name><name><surname>Nakamichi</surname><given-names>M</given-names></name><name><surname>Hiranita</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Shoyama</surname><given-names>Y</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name></person-group><article-title>Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade</article-title><source>Neuropsychopharmacology</source><year>2004</year><volume>29</volume><fpage>1470</fpage><lpage>1478</lpage><pub-id pub-id-type="pmid">15085091</pub-id></citation></ref><ref id="R4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arseneault</surname><given-names>L</given-names></name><name><surname>Cannon</surname><given-names>M</given-names></name><name><surname>Poulton</surname><given-names>R</given-names></name><name><surname>Murray</surname><given-names>R</given-names></name><name><surname>Caspi</surname><given-names>A</given-names></name><name><surname>Moffitt</surname><given-names>TE</given-names></name></person-group><article-title>Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study</article-title><source>BMJ</source><year>2002</year><volume>325</volume><fpage>1212</fpage><lpage>1213</lpage><pub-id pub-id-type="pmid">12446537</pub-id></citation></ref><ref id="R5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ashton</surname><given-names>JC</given-names></name><name><surname>Friberg</surname><given-names>D</given-names></name><name><surname>Darlington</surname><given-names>CL</given-names></name><name><surname>Smith</surname><given-names>PF</given-names></name></person-group><article-title>Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study</article-title><source>Neurosci. Lett.</source><year>2006</year><volume>396</volume><fpage>113</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">16356641</pub-id></citation></ref><ref id="R6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bahr</surname><given-names>BA</given-names></name><name><surname>Karanian</surname><given-names>DA</given-names></name><name><surname>Makanji</surname><given-names>SS</given-names></name><name><surname>Makriyannis</surname><given-names>A</given-names></name></person-group><article-title>Targeting the endocannabinoid system in treating brain disorders</article-title><source>Expert Opin. Investig. Drugs</source><year>2006</year><volume>15</volume><fpage>351</fpage><lpage>365</lpage></citation></ref><ref id="R7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Batkai</surname><given-names>S</given-names></name><name><surname>Jarai</surname><given-names>Z</given-names></name><name><surname>Wagner</surname><given-names>JA</given-names></name><name><surname>Goparaju</surname><given-names>SK</given-names></name><name><surname>Varga</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Mirshahi</surname><given-names>F</given-names></name><name><surname>Khanolkar</surname><given-names>AD</given-names></name><name><surname>Makriyannis</surname><given-names>A</given-names></name><name><surname>Urbaschek</surname><given-names>R</given-names></name><name><surname>Garcia N</surname><given-names>Jr</given-names></name><name><surname>Sanyal</surname><given-names>AJ</given-names></name><name><surname>Kunos</surname><given-names>G</given-names></name></person-group><article-title>Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis</article-title><source>Nat. Med.</source><year>2001</year><volume>7</volume><fpage>827</fpage><lpage>832</lpage><pub-id pub-id-type="pmid">11433348</pub-id></citation></ref><ref id="R8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bayer</surname><given-names>VE</given-names></name><name><surname>Pickel</surname><given-names>VM</given-names></name></person-group><article-title>GABA-labeled terminals form proportionally more synapses with dopaminergic neurons containing low densities of tyrosine hydroxylase-immunoreactivity in rat ventral tegmental area</article-title><source>Brain Res.</source><year>1991</year><volume>559</volume><fpage>44</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">1685938</pub-id></citation></ref><ref id="R9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beltramo</surname><given-names>M</given-names></name><name><surname>Stella</surname><given-names>N</given-names></name><name><surname>Calignano</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>SY</given-names></name><name><surname>Makriyannis</surname><given-names>A</given-names></name><name><surname>Piomelli</surname><given-names>D</given-names></name></person-group><article-title>Functional role of high-affinity anandamide transport, as revealed by selective inhibition</article-title><source>Science</source><year>1997</year><volume>277</volume><fpage>1094</fpage><lpage>1097</lpage><pub-id pub-id-type="pmid">9262477</pub-id></citation></ref><ref id="R10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>C</given-names></name><name><surname>Milh</surname><given-names>M</given-names></name><name><surname>Morozov</surname><given-names>YM</given-names></name><name><surname>Ben-Ari</surname><given-names>Y</given-names></name><name><surname>Freund</surname><given-names>TF</given-names></name><name><surname>Gozlan</surname><given-names>H</given-names></name></person-group><article-title>Altering cannabinoid signaling during development disrupts neuronal activity</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2005</year><volume>102</volume><fpage>9388</fpage><lpage>9393</lpage><pub-id pub-id-type="pmid">15964987</pub-id></citation></ref><ref id="R11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bisogno</surname><given-names>T</given-names></name><name><surname>Howell</surname><given-names>F</given-names></name><name><surname>Williams</surname><given-names>G</given-names></name><name><surname>Minassi</surname><given-names>A</given-names></name><name><surname>Cascio</surname><given-names>MG</given-names></name><name><surname>Ligresti</surname><given-names>A</given-names></name><name><surname>Matias</surname><given-names>I</given-names></name><name><surname>Schiano-Moriello</surname><given-names>A</given-names></name><name><surname>Paul</surname><given-names>P</given-names></name><name><surname>Williams</surname><given-names>EJ</given-names></name><name><surname>Gangadharan</surname><given-names>U</given-names></name><name><surname>Hobbs</surname><given-names>C</given-names></name><name><surname>Di Marzo</surname><given-names>V</given-names></name><name><surname>Doherty</surname><given-names>P</given-names></name></person-group><article-title>Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain</article-title><source>J. Cell Biol.</source><year>2003</year><volume>163</volume><fpage>463</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">14610053</pub-id></citation></ref><ref id="R12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blandini</surname><given-names>F</given-names></name><name><surname>Greenamyre</surname><given-names>JT</given-names></name><name><surname>Fancellu</surname><given-names>R</given-names></name><name><surname>Nappi</surname><given-names>G</given-names></name></person-group><article-title>Blockade of subthalamic glutamatergic activity corrects changes in neuronal metabolism and motor behavior in rats with nigrostriatal lesions</article-title><source>Neurol. Sci.</source><year>2001</year><volume>22</volume><fpage>49</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">11487196</pub-id></citation></ref><ref id="R13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blandini</surname><given-names>F</given-names></name><name><surname>Nappi</surname><given-names>G</given-names></name><name><surname>Tassorelli</surname><given-names>C</given-names></name><name><surname>Martignoni</surname><given-names>E</given-names></name></person-group><article-title>Functional changes of the basal ganglia circuitry in Parkinson's disease</article-title><source>Prog. Neurobiol.</source><year>2000</year><volume>62</volume><fpage>63</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">10821982</pub-id></citation></ref><ref id="R14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bouaboula</surname><given-names>M</given-names></name><name><surname>Perrachon</surname><given-names>S</given-names></name><name><surname>Milligan</surname><given-names>L</given-names></name><name><surname>Canat</surname><given-names>X</given-names></name><name><surname>Rinaldi-Carmona</surname><given-names>M</given-names></name><name><surname>Portier</surname><given-names>M</given-names></name><name><surname>Barth</surname><given-names>F</given-names></name><name><surname>Calandra</surname><given-names>B</given-names></name><name><surname>Pecceu</surname><given-names>F</given-names></name><name><surname>Lupker</surname><given-names>J</given-names></name><name><surname>Maffrand</surname><given-names>JP</given-names></name><name><surname>Le Fur</surname><given-names>G</given-names></name><name><surname>Casellas</surname><given-names>P</given-names></name></person-group><article-title>A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1.Evidence for a new model of receptor/ligand interactions. </article-title><source>J. Biol. Chem.</source><year>1997</year><volume>272</volume><fpage>22330</fpage><lpage>22339</lpage><pub-id pub-id-type="pmid">9268384</pub-id></citation></ref><ref id="R15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brenowitz</surname><given-names>SD</given-names></name><name><surname>Regehr</surname><given-names>WG</given-names></name></person-group><article-title>Associative short-term synaptic plasticity mediated by endocannabinoids</article-title><source>Neuron</source><year>2005</year><volume>45</volume><fpage>419</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">15694328</pub-id></citation></ref><ref id="R16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brotchie</surname><given-names>JM</given-names></name></person-group><article-title>CB1 cannabinoid receptor signalling in Parkinson's disease</article-title><source>Curr. Opin. Pharmacol.</source><year>2003</year><volume>3</volume><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">12550742</pub-id></citation></ref><ref id="R17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>SP</given-names></name><name><surname>Brenowitz</surname><given-names>SD</given-names></name><name><surname>Regehr</surname><given-names>WG</given-names></name></person-group><article-title>Brief presynaptic bursts evoke synapse-specific retrograde inhibition mediated by endogenous cannabinoids</article-title><source>Nat. Neurosci.</source><year>2003</year><volume>6</volume><fpage>1048</fpage><lpage>1057</lpage><pub-id pub-id-type="pmid">14502290</pub-id></citation></ref><ref id="R18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cadas</surname><given-names>H</given-names></name><name><surname>Gaillet</surname><given-names>S</given-names></name><name><surname>Beltramo</surname><given-names>M</given-names></name><name><surname>Venance</surname><given-names>L</given-names></name><name><surname>Piomelli</surname><given-names>D</given-names></name></person-group><article-title>Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP</article-title><source>J. Neurosci.</source><year>1996</year><volume>16</volume><fpage>3934</fpage><lpage>3942</lpage><pub-id pub-id-type="pmid">8656287</pub-id></citation></ref><ref id="R19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calabresi</surname><given-names>P</given-names></name><name><surname>Centonze</surname><given-names>D</given-names></name><name><surname>Gubellini</surname><given-names>P</given-names></name><name><surname>Marfia</surname><given-names>GA</given-names></name><name><surname>Pisani</surname><given-names>A</given-names></name><name><surname>Sancesario</surname><given-names>G</given-names></name><name><surname>Bernardi</surname><given-names>G</given-names></name></person-group><article-title>Synaptic transmission in the striatum: from plasticity to neurodegeneration</article-title><source>Prog. Neurobiol.</source><year>2000</year><volume>61</volume><fpage>231</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">10727775</pub-id></citation></ref><ref id="R20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calabresi</surname><given-names>P</given-names></name><name><surname>Mercuri</surname><given-names>NB</given-names></name><name><surname>Sancesario</surname><given-names>G</given-names></name><name><surname>Bernardi</surname><given-names>G</given-names></name></person-group><article-title>Electrophysiology of dopamine-denervated striatal neurons Implications for Parkinson's disease</article-title><source>Brai</source><year>1993</year><volume>116</volume><issue>Pt 2</issue><fpage>433</fpage><lpage>452</lpage></citation></ref><ref id="R21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calabresi</surname><given-names>P</given-names></name><name><surname>Pisani</surname><given-names>A</given-names></name><name><surname>Mercuri</surname><given-names>NB</given-names></name><name><surname>Bernardi</surname><given-names>G</given-names></name></person-group><article-title>The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia</article-title><source>Trends Neurosci.</source><year>1996</year><volume>19</volume><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">8787136</pub-id></citation></ref><ref id="R22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caspi</surname><given-names>A</given-names></name><name><surname>Moffitt</surname><given-names>TE</given-names></name><name><surname>Cannon</surname><given-names>M</given-names></name><name><surname>McClay</surname><given-names>J</given-names></name><name><surname>Murray</surname><given-names>R</given-names></name><name><surname>Harrington</surname><given-names>H</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name><name><surname>Arseneault</surname><given-names>L</given-names></name><name><surname>Williams</surname><given-names>B</given-names></name><name><surname>Braithwaite</surname><given-names>A</given-names></name><name><surname>Poulton</surname><given-names>R</given-names></name><name><surname>Craig</surname><given-names>IW</given-names></name></person-group><article-title>Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction</article-title><source>Biol. Psychiatry</source><year>2005</year><volume>57</volume><fpage>1117</fpage><lpage>1127</lpage><pub-id pub-id-type="pmid">15866551</pub-id></citation></ref><ref id="R23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Centonze</surname><given-names>D</given-names></name><name><surname>Picconi</surname><given-names>B</given-names></name><name><surname>Gubellini</surname><given-names>P</given-names></name><name><surname>Bernardi</surname><given-names>G</given-names></name><name><surname>Calabresi</surname><given-names>P</given-names></name></person-group><article-title>Dopaminergic control of synaptic plasticity in the dorsal striatum</article-title><source>Eur. J. Neurosci.</source><year>2001</year><volume>13</volume><fpage>1071</fpage><lpage>1077</lpage><pub-id pub-id-type="pmid">11285003</pub-id></citation></ref><ref id="R24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chase</surname><given-names>TN</given-names></name><name><surname>Oh</surname><given-names>JD</given-names></name></person-group><article-title>Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications Ann</article-title><source>Neurol discussion S129-130.</source><year>2000</year><volume>47</volume><fpage>S122</fpage><lpage>129</lpage></citation></ref><ref id="R25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheer</surname><given-names>JF</given-names></name><name><surname>Wassum</surname><given-names>KM</given-names></name><name><surname>Heien</surname><given-names>ML</given-names></name><name><surname>Phillips</surname><given-names>PE</given-names></name><name><surname>Wightman</surname><given-names>RM</given-names></name></person-group><article-title>Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats</article-title><source>J. Neurosci.</source><year>2004</year><volume>24</volume><fpage>4393</fpage><lpage>4400</lpage><pub-id pub-id-type="pmid">15128853</pub-id></citation></ref><ref id="R26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheer</surname><given-names>JF</given-names></name><name><surname>Wassum</surname><given-names>KM</given-names></name><name><surname>Sombers</surname><given-names>LA</given-names></name><name><surname>Heien</surname><given-names>ML</given-names></name><name><surname>Ariansen</surname><given-names>JL</given-names></name><name><surname>Aragona</surname><given-names>BJ</given-names></name><name><surname>Phillips</surname><given-names>PE</given-names></name><name><surname>Wightman</surname><given-names>RM</given-names></name></person-group><article-title>Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation</article-title><source>J. Neurosci</source><year>2007</year><volume>27</volume><fpage>791</fpage><lpage>795</lpage><pub-id pub-id-type="pmid">17251418</pub-id></citation></ref><ref id="R27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Bazan</surname><given-names>NG</given-names></name></person-group><article-title>Lipid signaling: sleep, synaptic plasticity, and neuroprotection</article-title><source>Prostaglandins Other Lipid Mediat.</source><year>2005</year><volume>77</volume><fpage>65</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">16099392</pub-id></citation></ref><ref id="R28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Paredes</surname><given-names>W</given-names></name><name><surname>Lowinson</surname><given-names>JH</given-names></name><name><surname>Gardner</surname><given-names>EL</given-names></name></person-group><article-title>Delta 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex</article-title><source>Eur. J. Pharmacol.</source><year>1990</year><volume>190</volume><fpage>259</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">1963849</pub-id></citation></ref><ref id="R29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Neu</surname><given-names>A</given-names></name><name><surname>Howard</surname><given-names>AL</given-names></name><name><surname>Foldy</surname><given-names>C</given-names></name><name><surname>Echegoyen</surname><given-names>J</given-names></name><name><surname>Hilgenberg</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>M</given-names></name><name><surname>Mackie</surname><given-names>K</given-names></name><name><surname>Soltesz</surname><given-names>I</given-names></name></person-group><article-title>Prevention of plasticity of endocannabinoid signaling inhibits persistent limbic hyperexcitability caused by developmental seizures</article-title><source>J. Neurosci.</source><year>2007</year><volume>27</volume><fpage>46</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">17202471</pub-id></citation></ref><ref id="R30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chevaleyre</surname><given-names>V</given-names></name><name><surname>Castillo</surname><given-names>PE</given-names></name></person-group><article-title>Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability</article-title><source>Neuron</source><year>2003</year><volume>38</volume><fpage>461</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">12741992</pub-id></citation></ref><ref id="R31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chevaleyre</surname><given-names>V</given-names></name><name><surname>Takahashi</surname><given-names>KA</given-names></name><name><surname>Castillo</surname><given-names>PE</given-names></name></person-group><article-title>Endocannabinoid-mediated synaptic plasticity in the CNS</article-title><source>Annu. Rev. Neurosci</source><year>2006</year><volume>29</volume><fpage>37</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">16776579</pub-id></citation></ref><ref id="R32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Childers</surname><given-names>SR</given-names></name><name><surname>Deadwyler</surname><given-names>SA</given-names></name></person-group><article-title>Role of cyclic AMP in the actions of cannabinoid receptors</article-title><source>Biochem. Pharmacol.</source><year>1996</year><volume>52</volume><fpage>819</fpage><lpage>827</lpage><pub-id pub-id-type="pmid">8781498</pub-id></citation></ref><ref id="R33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>C</given-names></name><name><surname>Kodas</surname><given-names>E</given-names></name><name><surname>Griebel</surname><given-names>G</given-names></name></person-group><article-title>CB1 receptor antagonists for the treatment of nicotine addiction</article-title><source>Pharmacol. Biochem. Behav.</source><year>2005</year><volume>81</volume><fpage>387</fpage><lpage>395</lpage><pub-id pub-id-type="pmid">15935455</pub-id></citation></ref><ref id="R34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>C</given-names></name><name><surname>Perrault</surname><given-names>G</given-names></name><name><surname>Griebel</surname><given-names>G</given-names></name><name><surname>Soubrie</surname><given-names>P</given-names></name></person-group><article-title>Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716)</article-title><source>Neuropsychopharmacology</source><year>2005</year><volume>30</volume><fpage>145</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">15292905</pub-id></citation></ref><ref id="R35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>G</given-names></name><name><surname>Agabio</surname><given-names>R</given-names></name><name><surname>Fa</surname><given-names>M</given-names></name><name><surname>Guano</surname><given-names>L</given-names></name><name><surname>Lobina</surname><given-names>C</given-names></name><name><surname>Loche</surname><given-names>A</given-names></name><name><surname>Reali</surname><given-names>R</given-names></name><name><surname>Gessa</surname><given-names>GL</given-names></name></person-group><article-title>Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR-141716</article-title><source>Alcohol Alcohol</source><year>1998</year><volume>33</volume><fpage>126</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">9566474</pub-id></citation></ref><ref id="R36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cravatt</surname><given-names>BF</given-names></name><name><surname>Giang</surname><given-names>DK</given-names></name><name><surname>Mayfield</surname><given-names>SP</given-names></name><name><surname>Boger</surname><given-names>DL</given-names></name><name><surname>Lerner</surname><given-names>RA</given-names></name><name><surname>Gilula</surname><given-names>NB</given-names></name></person-group><article-title>Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides</article-title><source>Nature</source><year>1996</year><volume>384</volume><fpage>83</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">8900284</pub-id></citation></ref><ref id="R37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crawley</surname><given-names>JN</given-names></name><name><surname>Corwin</surname><given-names>RL</given-names></name><name><surname>Robinson</surname><given-names>JK</given-names></name><name><surname>Felder</surname><given-names>CC</given-names></name><name><surname>Devane</surname><given-names>WA</given-names></name><name><surname>Axelrod</surname><given-names>J</given-names></name></person-group><article-title>Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents</article-title><source>Pharmacol. Biochem. Behav.</source><year>1993</year><volume>46</volume><fpage>967</fpage><lpage>972</lpage><pub-id pub-id-type="pmid">7906042</pub-id></citation></ref><ref id="R38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Lago</surname><given-names>E</given-names></name><name><surname>Fernandez-Ruiz</surname><given-names>J</given-names></name><name><surname>Ortega-Gutierrez</surname><given-names>S</given-names></name><name><surname>Cabranes</surname><given-names>A</given-names></name><name><surname>Pryce</surname><given-names>G</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name><name><surname>Lopez-Rodriguez</surname><given-names>M</given-names></name><name><surname>Ramos</surname><given-names>JA</given-names></name></person-group><article-title>UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders</article-title><source>Eur. Neuropsychopharmacol</source><year>2006</year><volume>16</volume><fpage>7</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">16006105</pub-id></citation></ref><ref id="R39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Vries</surname><given-names>TJ</given-names></name><name><surname>Homberg</surname><given-names>JR</given-names></name><name><surname>Binnekade</surname><given-names>R</given-names></name><name><surname>Raaso</surname><given-names>H</given-names></name><name><surname>Schoffelmeer</surname><given-names>AN</given-names></name></person-group><article-title>Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats</article-title><source>Psychopharmacology (Berl.)</source><year>2003</year><volume>168</volume><fpage>164</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">12669182</pub-id></citation></ref><ref id="R40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Vries</surname><given-names>TJ</given-names></name><name><surname>Schoffelmeer</surname><given-names>AN</given-names></name></person-group><article-title>Cannabinoid CB1 receptors control conditioned drug seeking Trends Pharmacol</article-title><source>Trends Pharmacol. Sci.</source><year>2005</year><volume>26</volume><fpage>420</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">15992935</pub-id></citation></ref><ref id="R41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Vries</surname><given-names>TJ</given-names></name><name><surname>Shaham</surname><given-names>Y</given-names></name><name><surname>Homberg</surname><given-names>JR</given-names></name><name><surname>Crombag</surname><given-names>H</given-names></name><name><surname>Schuurman</surname><given-names>K</given-names></name><name><surname>Dieben</surname><given-names>J</given-names></name><name><surname>Vanderschuren</surname><given-names>LJ</given-names></name><name><surname>Schoffelmeer</surname><given-names>AN</given-names></name></person-group><article-title>A cannabinoid mechanism in relapse to cocaine seeking</article-title><source>Nat. Med.</source><year>2001</year><volume>7</volume><fpage>1151</fpage><lpage>1154</lpage><pub-id pub-id-type="pmid">11590440</pub-id></citation></ref><ref id="R42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Derkinderen</surname><given-names>P</given-names></name><name><surname>Toutant</surname><given-names>M</given-names></name><name><surname>Burgaya</surname><given-names>F</given-names></name><name><surname>Le Bert</surname><given-names>M</given-names></name><name><surname>Siciliano</surname><given-names>JC</given-names></name><name><surname>de Franciscis</surname><given-names>V</given-names></name><name><surname>Gelman</surname><given-names>M</given-names></name><name><surname>Girault</surname><given-names>JA</given-names></name></person-group><article-title>Regulation of a neuronal form of focal adhesion kinase by anandamide</article-title><source>Science</source><year>1996</year><volume>273</volume><fpage>1719</fpage><lpage>1722</lpage><pub-id pub-id-type="pmid">8781236</pub-id></citation></ref><ref id="R43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Devane</surname><given-names>WA</given-names></name><name><surname>Dysarz FA</surname><given-names>3rd</given-names></name><name><surname>Johnson</surname><given-names>MR</given-names></name><name><surname>Melvin</surname><given-names>LS</given-names></name><name><surname>Howlett</surname><given-names>AC</given-names></name></person-group><article-title>Determination and characterization of a cannabinoid receptor in rat brain</article-title><source>Mol. Pharmacol.</source><year>1988</year><volume>34</volume><fpage>605</fpage><lpage>613</lpage><pub-id pub-id-type="pmid">2848184</pub-id></citation></ref><ref id="R44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Devane</surname><given-names>WA</given-names></name><name><surname>Hanus</surname><given-names>L</given-names></name><name><surname>Breuer</surname><given-names>A</given-names></name><name><surname>Pertwee</surname><given-names>RG</given-names></name><name><surname>Stevenson</surname><given-names>LA</given-names></name><name><surname>Griffin</surname><given-names>G</given-names></name><name><surname>Gibson</surname><given-names>D</given-names></name><name><surname>Mandelbaum</surname><given-names>A</given-names></name><name><surname>Etinger</surname><given-names>A</given-names></name><name><surname>Mechoulam</surname><given-names>R</given-names></name></person-group><article-title>Isolation and structure of a brain constituent that binds to the cannabinoid receptor</article-title><source>Science</source><year>1992</year><volume>258</volume><fpage>1946</fpage><lpage>1949</lpage><pub-id pub-id-type="pmid">1470919</pub-id></citation></ref><ref id="R45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Marzo</surname><given-names>V</given-names></name></person-group><article-title>'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties biochemistry and possible physiopathological relevance Biochim</article-title><source>Biophys. Acta</source><year>1998</year><volume>1392</volume><fpage>153</fpage><lpage>175</lpage></citation></ref><ref id="R46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Marzo</surname><given-names>V</given-names></name><name><surname>Fontana</surname><given-names>A</given-names></name><name><surname>Cadas</surname><given-names>H</given-names></name><name><surname>Schinelli</surname><given-names>S</given-names></name><name><surname>Cimino</surname><given-names>G</given-names></name><name><surname>Schwartz</surname><given-names>JC</given-names></name><name><surname>Piomelli</surname><given-names>D</given-names></name></person-group><article-title>Formation and inactivation of endogenous cannabinoid anandamide in central neurons</article-title><source>Nature</source><year>1994</year><volume>372</volume><fpage>686</fpage><lpage>691</lpage><pub-id pub-id-type="pmid">7990962</pub-id></citation></ref><ref id="R47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Marzo</surname><given-names>V</given-names></name><name><surname>Hill</surname><given-names>MP</given-names></name><name><surname>Bisogno</surname><given-names>T</given-names></name><name><surname>Crossman</surname><given-names>AR</given-names></name><name><surname>Brotchie</surname><given-names>JM</given-names></name></person-group><article-title>Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease</article-title><source>FASEB J.</source><year>2000</year><volume>14</volume><fpage>1432</fpage><lpage>1438</lpage><pub-id pub-id-type="pmid">10877836</pub-id></citation></ref><ref id="R48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diana</surname><given-names>MA</given-names></name><name><surname>Marty</surname><given-names>A</given-names></name></person-group><article-title>Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE)</article-title><source>Br. J. Pharmacol.</source><year>2004</year><volume>142</volume><fpage>9</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">15100161</pub-id></citation></ref><ref id="R49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dinh</surname><given-names>TP</given-names></name><name><surname>Carpenter</surname><given-names>D</given-names></name><name><surname>Leslie</surname><given-names>FM</given-names></name><name><surname>Freund</surname><given-names>TF</given-names></name><name><surname>Katona</surname><given-names>I</given-names></name><name><surname>Sensi</surname><given-names>SL</given-names></name><name><surname>Kathuria</surname><given-names>S</given-names></name><name><surname>Piomelli</surname><given-names>D</given-names></name></person-group><article-title>Brain monoglyceride lipase participating in endocannabinoid inactivation</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2002</year><volume>99</volume><fpage>10819</fpage><lpage>10824</lpage><pub-id pub-id-type="pmid">12136125</pub-id></citation></ref><ref id="R50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dirnagl</surname><given-names>U</given-names></name><name><surname>Iadecola</surname><given-names>C</given-names></name><name><surname>Moskowitz</surname><given-names>MA</given-names></name></person-group><article-title>Pathobiology of ischaemic stroke: an integrated view</article-title><source>Trends Neurosci</source><year>1999</year><volume>22</volume><fpage>391</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">10441299</pub-id></citation></ref><ref id="R51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drysdale</surname><given-names>AJ</given-names></name><name><surname>Platt</surname><given-names>B</given-names></name></person-group><article-title>Cannabinoids: mechanisms and therapeutic applications in the CNS</article-title><source>Curr. Med. Chem.</source><year>2003</year><volume>10</volume><fpage>2719</fpage><lpage>2732</lpage><pub-id pub-id-type="pmid">14529462</pub-id></citation></ref><ref id="R52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fattore</surname><given-names>L</given-names></name><name><surname>Spano</surname><given-names>MS</given-names></name><name><surname>Cossu</surname><given-names>G</given-names></name><name><surname>Deiana</surname><given-names>S</given-names></name><name><surname>Fratta</surname><given-names>W</given-names></name></person-group><article-title>Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats</article-title><source>Eur. J. Neurosci.</source><year>2003</year><volume>17</volume><fpage>1723</fpage><lpage>1726</lpage><pub-id pub-id-type="pmid">12752390</pub-id></citation></ref><ref id="R53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fattore</surname><given-names>L</given-names></name><name><surname>Spano</surname><given-names>S</given-names></name><name><surname>Cossu</surname><given-names>G</given-names></name><name><surname>Deiana</surname><given-names>S</given-names></name><name><surname>Fadda</surname><given-names>P</given-names></name><name><surname>Fratta</surname><given-names>W</given-names></name></person-group><article-title>Cannabinoid CB(1) antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats</article-title><source>Neuropharmacology</source><year>2005</year><volume>48</volume><fpage>1097</fpage><lpage>1104</lpage><pub-id pub-id-type="pmid">15910886</pub-id></citation></ref><ref id="R54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Espejo</surname><given-names>E</given-names></name><name><surname>Caraballo</surname><given-names>I</given-names></name><name><surname>Rodriguez de Fonseca</surname><given-names>F</given-names></name><name><surname>Ferrer</surname><given-names>B</given-names></name><name><surname>El Banoua</surname><given-names>F</given-names></name><name><surname>Flores</surname><given-names>JA</given-names></name><name><surname>Galan-Rodriguez</surname><given-names>B</given-names></name></person-group><article-title>Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function</article-title><source>Neuropsychopharmacology</source><year>2004</year><volume>29</volume><fpage>1134</fpage><lpage>1142</lpage><pub-id pub-id-type="pmid">15010694</pub-id></citation></ref><ref id="R55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrer</surname><given-names>B</given-names></name><name><surname>Asbrock</surname><given-names>N</given-names></name><name><surname>Kathuria</surname><given-names>S</given-names></name><name><surname>Piomelli</surname><given-names>D</given-names></name><name><surname>Giuffrida</surname><given-names>A</given-names></name></person-group><article-title>Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias</article-title><source>Eur. J. Neurosci.</source><year>2003</year><volume>18</volume><fpage>1607</fpage><lpage>1614</lpage><pub-id pub-id-type="pmid">14511339</pub-id></citation></ref><ref id="R56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fowler</surname><given-names>CJ</given-names></name></person-group><article-title>Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents Non-psychoactive cannabinoids, 'entourage' compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid pyschotropic effects</article-title><source>Brain Res. Brain Res. Rev.</source><year>2003</year><volume>41</volume><fpage>26</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">12505646</pub-id></citation></ref><ref id="R57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>French</surname><given-names>ED</given-names></name><name><surname>Dillon</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name></person-group><article-title>Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra</article-title><source>Neuroreport</source><year>1997</year><volume>8</volume><fpage>649</fpage><lpage>652</lpage><pub-id pub-id-type="pmid">9106740</pub-id></citation></ref><ref id="R58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fride</surname><given-names>E</given-names></name><name><surname>Mechoulam</surname><given-names>R</given-names></name></person-group><article-title>Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent</article-title><source>Eur. J. Pharmacol</source><year>1993</year><volume>231</volume><fpage>313</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">8384116</pub-id></citation></ref><ref id="R59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galiegue</surname><given-names>S</given-names></name><name><surname>Mary</surname><given-names>S</given-names></name><name><surname>Marchand</surname><given-names>J</given-names></name><name><surname>Dussossoy</surname><given-names>D</given-names></name><name><surname>Carriere</surname><given-names>D</given-names></name><name><surname>Carayon</surname><given-names>P</given-names></name><name><surname>Bouaboula</surname><given-names>M</given-names></name><name><surname>Shire</surname><given-names>D</given-names></name><name><surname>Le Fur</surname><given-names>G</given-names></name><name><surname>Casellas</surname><given-names>P</given-names></name></person-group><article-title>Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations</article-title><source>Eur. J. Biochem</source><year>1995</year><volume>232</volume><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">7556170</pub-id></citation></ref><ref id="R60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gallate</surname><given-names>JE</given-names></name><name><surname>McGregor</surname><given-names>IS</given-names></name></person-group><article-title>The motivation for beer in rats: effects of ritanserin, naloxone and SR 141716</article-title><source>Psychopharmacology (Berl.)</source><year>1999</year><volume>142</volume><fpage>302</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">10208323</pub-id></citation></ref><ref id="R61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gallate</surname><given-names>JE</given-names></name><name><surname>Saharov</surname><given-names>T</given-names></name><name><surname>Mallet</surname><given-names>PE</given-names></name><name><surname>McGregor</surname><given-names>IS</given-names></name></person-group><article-title>Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist</article-title><source>Eur. J. Pharmacol.</source><year>1999</year><volume>370</volume><fpage>233</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">10334497</pub-id></citation></ref><ref id="R62"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galve-Roperh</surname><given-names>I</given-names></name><name><surname>Sanchez</surname><given-names>C</given-names></name><name><surname>Cortes</surname><given-names>ML</given-names></name><name><surname>del Pulgar</surname><given-names>TG</given-names></name><name><surname>Izquierdo</surname><given-names>M</given-names></name><name><surname>Guzman</surname><given-names>M</given-names></name></person-group><article-title>Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation</article-title><source>Nat. Med.</source><year>2000</year><volume>6</volume><fpage>313</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">10700234</pub-id></citation></ref><ref id="R63"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Arencibia</surname><given-names>M</given-names></name><name><surname>Gonzalez</surname><given-names>S</given-names></name><name><surname>de Lago</surname><given-names>E</given-names></name><name><surname>Ramos</surname><given-names>JA</given-names></name><name><surname>Mechoulam</surname><given-names>R</given-names></name><name><surname>Fernandez-Ruiz</surname><given-names>J</given-names></name></person-group><article-title>Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease importance of antioxidant and cannabinoid receptor-independent properties</article-title><source>Brain Res.</source><year>2007</year><volume>1134</volume><fpage>162</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">17196181</pub-id></citation></ref><ref id="R64"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gardner</surname><given-names>EL</given-names></name></person-group><article-title>Endocannabinoid signaling system and brain reward: emphasis on dopamine</article-title><source>Pharmacol. Biochem. Behav</source><year>2005</year><volume>81</volume><fpage>263</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">15936806</pub-id></citation></ref><ref id="R65"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gebremedhin</surname><given-names>D</given-names></name><name><surname>Lange</surname><given-names>AR</given-names></name><name><surname>Campbell</surname><given-names>WB</given-names></name><name><surname>Hillard</surname><given-names>CJ</given-names></name><name><surname>Harder</surname><given-names>DR</given-names></name></person-group><article-title>Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current</article-title><source>Am. J. Physiol.</source><year>1999</year><volume>276</volume><fpage>H2085</fpage><lpage>2093</lpage><pub-id pub-id-type="pmid">10362691</pub-id></citation></ref><ref id="R66"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gerdeman</surname><given-names>G</given-names></name><name><surname>Lovinger</surname><given-names>DM</given-names></name></person-group><article-title>CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum</article-title><source>J. Neurophysiol.</source><year>2001</year><volume>85</volume><fpage>468</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">11152748</pub-id></citation></ref><ref id="R67"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gerdeman</surname><given-names>GL</given-names></name><name><surname>Lovinger</surname><given-names>DM</given-names></name></person-group><article-title>Emerging roles for endocannabinoids in long-term synaptic plasticity</article-title><source>Br. J. Pharmacol.</source><year>2003</year><volume>140</volume><fpage>781</fpage><lpage>789</lpage><pub-id pub-id-type="pmid">14504143</pub-id></citation></ref><ref id="R68"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gerdeman</surname><given-names>GL</given-names></name><name><surname>Partridge</surname><given-names>JG</given-names></name><name><surname>Lupica</surname><given-names>CR</given-names></name><name><surname>Lovinger</surname><given-names>DM</given-names></name></person-group><article-title>It could be habit forming: drugs of abuse and striatal synaptic plasticity</article-title><source>Trends Neurosci.</source><year>2003</year><volume>26</volume><fpage>184</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">12689769</pub-id></citation></ref><ref id="R69"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gerdeman</surname><given-names>GL</given-names></name><name><surname>Ronesi</surname><given-names>J</given-names></name><name><surname>Lovinger</surname><given-names>DM</given-names></name></person-group><article-title>Postsynaptic endocannabinoid release is critical to long-term depression in the striatum</article-title><source>Nat.  Neurosci.</source><year>2002</year><volume>5</volume><fpage>446</fpage><lpage>451</lpage><pub-id pub-id-type="pmid">11976704</pub-id></citation></ref><ref id="R70"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gessa</surname><given-names>GL</given-names></name><name><surname>Melis</surname><given-names>M</given-names></name><name><surname>Muntoni</surname><given-names>AL</given-names></name><name><surname>Diana</surname><given-names>M</given-names></name></person-group><article-title>Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors</article-title><source>Eur. J. Pharmacol</source><year>1998</year><volume>341</volume><fpage>39</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">9489854</pub-id></citation></ref><ref id="R71"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giuffrida</surname><given-names>A</given-names></name><name><surname>Beltramo</surname><given-names>M</given-names></name><name><surname>Piomelli</surname><given-names>D</given-names></name></person-group><article-title>Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2001</year><volume>298</volume><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">11408519</pub-id></citation></ref><ref id="R72"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giuffrida</surname><given-names>A</given-names></name><name><surname>Leweke</surname><given-names>FM</given-names></name><name><surname>Gerth</surname><given-names>CW</given-names></name><name><surname>Schreiber</surname><given-names>D</given-names></name><name><surname>Koethe</surname><given-names>D</given-names></name><name><surname>Faulhaber</surname><given-names>J</given-names></name><name><surname>Klosterkotter</surname><given-names>J</given-names></name><name><surname>Piomelli</surname><given-names>D</given-names></name></person-group><article-title>Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms</article-title><source>Neuropsychopharmacology</source><year>2004</year><volume>29</volume><fpage>2108</fpage><lpage>2114</lpage><pub-id pub-id-type="pmid">15354183</pub-id></citation></ref><ref id="R73"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giuffrida</surname><given-names>A</given-names></name><name><surname>Parsons</surname><given-names>LH</given-names></name><name><surname>Kerr</surname><given-names>TM</given-names></name><name><surname>Rodriguez de Fonseca</surname><given-names>F</given-names></name><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>Piomelli</surname><given-names>D</given-names></name></person-group><article-title>Dopamine activation of endogenous cannabinoid signaling in dorsal striatum</article-title><source>Nat. Neurosci.</source><year>1999</year><volume>2</volume><fpage>358</fpage><lpage>363</lpage><pub-id pub-id-type="pmid">10204543</pub-id></citation></ref><ref id="R74"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gonon</surname><given-names>FG</given-names></name></person-group><article-title>Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry</article-title><source>Neuroscience</source><year>1988</year><volume>24</volume><fpage>19</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">3368048</pub-id></citation></ref><ref id="R75"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grace</surname><given-names>AA</given-names></name><name><surname>Bunney</surname><given-names>BS</given-names></name></person-group><article-title>Intracellular and extracellular electrophysiology of nigral dopaminergic neurons--1.Identification and characterization</article-title><source> Neuroscience</source><year>1983</year><volume>10</volume><fpage>301</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">6633863</pub-id></citation></ref><ref id="R76"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>B</given-names></name><name><surname>Kavanagh</surname><given-names>D</given-names></name><name><surname>Young</surname><given-names>R</given-names></name></person-group><article-title>Being stoned: a review of self-reported cannabis effects</article-title><source>Drug Alcohol Rev</source><year>2003</year><volume>22</volume><fpage>453</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">14660135</pub-id></citation></ref><ref id="R77"><label>77</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Groenewegen</surname><given-names>HJ</given-names></name><name><surname>Berendse</surname><given-names>HW</given-names></name><name><surname>Haber</surname><given-names>SN</given-names></name></person-group><article-title>Organization of the output of the ventral striatopallidal system in the rat: ventral pallidal efferents</article-title><source>Neuroscience</source><year>1993</year><volume>57</volume><fpage>113</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">8278047</pub-id></citation></ref><ref id="R78"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grundy</surname><given-names>RI</given-names></name></person-group><article-title>The therapeutic potential of the cannabinoids in neuroprotection</article-title><source>Expert Opin. Investig. Drugs</source><year>2002</year><volume>11</volume><fpage>1365</fpage><lpage>1374</lpage></citation></ref><ref id="R79"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grundy</surname><given-names>RI</given-names></name><name><surname>Rabuffetti</surname><given-names>M</given-names></name><name><surname>Beltramo</surname><given-names>M</given-names></name></person-group><article-title>Cannabinoids and neuroprotection</article-title><source>Mol. Neurobiol.</source><year>2001</year><volume>24</volume><fpage>29</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">11831553</pub-id></citation></ref><ref id="R80"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gubellini</surname><given-names>P</given-names></name><name><surname>Picconi</surname><given-names>B</given-names></name><name><surname>Bari</surname><given-names>M</given-names></name><name><surname>Battista</surname><given-names>N</given-names></name><name><surname>Calabresi</surname><given-names>P</given-names></name><name><surname>Centonze</surname><given-names>D</given-names></name><name><surname>Bernardi</surname><given-names>G</given-names></name><name><surname>Finazzi-Agro</surname><given-names>A</given-names></name><name><surname>Maccarrone</surname><given-names>M</given-names></name></person-group><article-title>Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission</article-title><source>J. Neurosci.</source><year>2002</year><volume>22</volume><fpage>6900</fpage><lpage>6907</lpage><pub-id pub-id-type="pmid">12177188</pub-id></citation></ref><ref id="R81"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hajos</surname><given-names>M</given-names></name><name><surname>Greenfield</surname><given-names>SA</given-names></name></person-group><article-title>Synaptic connections between pars compacta and pars reticulata neurones: electrophysiological evidence for functional modules within the substantia nigra</article-title><source>Brain Res.</source><year>1994</year><volume>660</volume><fpage>216</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">7820690</pub-id></citation></ref><ref id="R82"><label>82</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hajos</surname><given-names>N</given-names></name><name><surname>Ledent</surname><given-names>C</given-names></name><name><surname>Freund</surname><given-names>TF</given-names></name></person-group><article-title>Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus</article-title><source>Neuroscience</source><year>2001</year><volume>106</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">11564411</pub-id></citation></ref><ref id="R83"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>HH</given-names></name><name><surname>Hansen</surname><given-names>SH</given-names></name><name><surname>Schousboe</surname><given-names>A</given-names></name><name><surname>Hansen</surname><given-names>HS</given-names></name></person-group><article-title>Determination of the phospholipid precursor of anandamide and other N-acylethanolamine phospholipids before and after sodium azide-induced toxicity in cultured neocortical neurons</article-title><source>J. Neurochem</source><year>2000</year><volume>75</volume><fpage>861</fpage><lpage>871</lpage><pub-id pub-id-type="pmid">10899965</pub-id></citation></ref><ref id="R84"><label>84</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herkenham</surname><given-names>M</given-names></name><name><surname>Lynn</surname><given-names>AB</given-names></name><name><surname>Johnson</surname><given-names>MR</given-names></name><name><surname>Melvin</surname><given-names>LS</given-names></name><name><surname>de Costa</surname><given-names>BR</given-names></name><name><surname>Rice</surname><given-names>KC</given-names></name></person-group><article-title>Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study</article-title><source>J. Neurosci.</source><year>1991</year><volume>11</volume><fpage>563</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">1992016</pub-id></citation></ref><ref id="R85"><label>85</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herkenham</surname><given-names>M</given-names></name><name><surname>Lynn</surname><given-names>AB</given-names></name><name><surname>Little</surname><given-names>MD</given-names></name><name><surname>Johnson</surname><given-names>MR</given-names></name><name><surname>Melvin</surname><given-names>LS</given-names></name><name><surname>de Costa</surname><given-names>BR</given-names></name><name><surname>Rice</surname><given-names>KC</given-names></name></person-group><article-title>Cannabinoid receptor localization in brain</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1990</year><volume>87</volume><fpage>1932</fpage><lpage>1936</lpage><pub-id pub-id-type="pmid">2308954</pub-id></citation></ref><ref id="R86"><label>86</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hillard</surname><given-names>CJ</given-names></name></person-group><article-title>Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol</article-title><source>Prostaglandins Other Lipid Mediat.</source><year>2000</year><volume>61</volume><fpage>3</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">10785538</pub-id></citation></ref><ref id="R87"><label>87</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hillard</surname><given-names>CJ</given-names></name><name><surname>Jarrahian</surname><given-names>A</given-names></name></person-group><article-title>The movement of N-arachidonoylethanol-amine (anandamide) across cellular membranes</article-title><source>Chem. Phys. Lipids</source><year>2000</year><volume>108</volume><fpage>123</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">11106786</pub-id></citation></ref><ref id="R88"><label>88</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Howlett</surname><given-names>AC</given-names></name></person-group><article-title>The cannabinoid receptors</article-title><source>Prostaglandins Other Lipid Mediat.</source><year>2002</year><volume>68-69</volume><fpage>619</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">12432948</pub-id></citation></ref><ref id="R89"><label>89</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Howlett</surname><given-names>AC</given-names></name><name><surname>Barth</surname><given-names>F</given-names></name><name><surname>Bonner</surname><given-names>TI</given-names></name><name><surname>Cabral</surname><given-names>G</given-names></name><name><surname>Casellas</surname><given-names>P</given-names></name><name><surname>Devane</surname><given-names>WA</given-names></name><name><surname>Felder</surname><given-names>CC</given-names></name><name><surname>Herkenham</surname><given-names>M</given-names></name><name><surname>Mackie</surname><given-names>K</given-names></name><name><surname>Martin</surname><given-names>BR</given-names></name><name><surname>Mechoulam</surname><given-names>R</given-names></name><name><surname>Pertwee</surname><given-names>RG</given-names></name></person-group><article-title>International Union of Pharmacology. XXVII.Classification of cannabinoid receptors</article-title><source> Pharmacol. Rev.</source><year>2002</year><volume>54</volume><fpage>161</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">12037135</pub-id></citation></ref><ref id="R90"><label>90</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Howlett</surname><given-names>AC</given-names></name><name><surname>Bidaut-Russell</surname><given-names>M</given-names></name><name><surname>Devane</surname><given-names>WA</given-names></name><name><surname>Melvin</surname><given-names>LS</given-names></name><name><surname>Johnson</surname><given-names>MR</given-names></name><name><surname>Herkenham</surname><given-names>M</given-names></name></person-group><article-title>The cannabinoid receptor biochemical, anatomical and behavioral characterization</article-title><source>Trends Neurosci.</source><year>1990</year><volume>13</volume><fpage>420</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">1700516</pub-id></citation></ref><ref id="R91"><label>91</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Howlett</surname><given-names>AC</given-names></name><name><surname>Johnson</surname><given-names>MR</given-names></name><name><surname>Melvin</surname><given-names>LS</given-names></name></person-group><article-title>Classical and nonclassical cannabinoids: mechanism of action--brain binding</article-title><source>NIDA Res. Monogr.</source><year>1990</year><volume>96</volume><fpage>100</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">2172821</pub-id></citation></ref><ref id="R92"><label>92</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Lo</surname><given-names>SW</given-names></name><name><surname>Hsu</surname><given-names>KS</given-names></name></person-group><article-title>Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons</article-title><source>J. Physiol.</source><year>2001</year><volume>532</volume><fpage>731</fpage><lpage>748</lpage><pub-id pub-id-type="pmid">11313442</pub-id></citation></ref><ref id="R93"><label>93</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hungund</surname><given-names>BL</given-names></name><name><surname>Szakall</surname><given-names>I</given-names></name><name><surname>Adam</surname><given-names>A</given-names></name><name><surname>Basavarajappa</surname><given-names>BS</given-names></name><name><surname>Vadasz</surname><given-names>C</given-names></name></person-group><article-title>Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens</article-title><source>J. Neurochem</source><year>2003</year><volume>84</volume><fpage>698</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">12562514</pub-id></citation></ref><ref id="R94"><label>94</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jonsson</surname><given-names>KO</given-names></name><name><surname>Holt</surname><given-names>S</given-names></name><name><surname>Fowler</surname><given-names>CJ</given-names></name></person-group><article-title>The endocannabinoid system: current pharmacological research and therapeutic possibilities</article-title><source>Basic Clin. Pharmacol. Toxicol.</source><year>2006</year><volume>98</volume><fpage>124</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">16445584</pub-id></citation></ref><ref id="R95"><label>95</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karanian</surname><given-names>DA</given-names></name><name><surname>Brown</surname><given-names>QB</given-names></name><name><surname>Makriyannis</surname><given-names>A</given-names></name><name><surname>Kosten</surname><given-names>TA</given-names></name><name><surname>Bahr</surname><given-names>BA</given-names></name></person-group><article-title>Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity</article-title><source>J. Neurosci.</source><year>2005</year><volume>25</volume><fpage>7813</fpage><lpage>7820</lpage><pub-id pub-id-type="pmid">16120783</pub-id></citation></ref><ref id="R96"><label>96</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Isokawa</surname><given-names>M</given-names></name><name><surname>Ledent</surname><given-names>C</given-names></name><name><surname>Alger</surname><given-names>BE</given-names></name></person-group><article-title>Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus</article-title><source>J. Neurosci.</source><year>2002</year><volume>22</volume><fpage>10182</fpage><lpage>10191</lpage><pub-id pub-id-type="pmid">12451119</pub-id></citation></ref><ref id="R97"><label>97</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Won</surname><given-names>SJ</given-names></name><name><surname>Mao</surname><given-names>XO</given-names></name><name><surname>Jin</surname><given-names>K</given-names></name><name><surname>Greenberg</surname><given-names>DA</given-names></name></person-group><article-title>Involvement of protein kinase A in cannabinoid receptor-mediated protection from oxidative neuronal injury</article-title><source>J. Pharmacol. Exp. Ther</source><year>2005</year><volume>313</volume><fpage>88</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">15626718</pub-id></citation></ref><ref id="R98"><label>98</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SR</given-names></name><name><surname>Lee da</surname><given-names>Y</given-names></name><name><surname>Chung</surname><given-names>ES</given-names></name><name><surname>Oh</surname><given-names>UT</given-names></name><name><surname>Kim</surname><given-names>SU</given-names></name><name><surname>Jin</surname><given-names>BK</given-names></name></person-group><article-title>Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons <italic>in vivo</italic> and in vitro</article-title><source>J. Neurosci.</source><year>2005</year><volume>25</volume><fpage>662</fpage><lpage>671</lpage><pub-id pub-id-type="pmid">15659603</pub-id></citation></ref><ref id="R99"><label>99</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kogan</surname><given-names>NM</given-names></name><name><surname>Mechoulam</surname><given-names>R</given-names></name></person-group><article-title>The chemistry of endocannabinoids</article-title><source>J. Endocrinol. Invest.</source><year>2006</year><volume>29</volume><fpage>3</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">16751705</pub-id></citation></ref><ref id="R100"><label>100</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Korotkova</surname><given-names>TM</given-names></name><name><surname>Ponomarenko</surname><given-names>AA</given-names></name><name><surname>Brown</surname><given-names>RE</given-names></name><name><surname>Haas</surname><given-names>HL</given-names></name></person-group><article-title>Functional diversity of ventral midbrain dopamine and GABAergic neurons</article-title><source>Mol. Neurobiol</source><year>2004</year><volume>29</volume><fpage>243</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">15181237</pub-id></citation></ref><ref id="R101"><label>101</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kovasznay</surname><given-names>B</given-names></name><name><surname>Fleischer</surname><given-names>J</given-names></name><name><surname>Tanenberg-Karant</surname><given-names>M</given-names></name><name><surname>Jandorf</surname><given-names>L</given-names></name><name><surname>Miller</surname><given-names>AD</given-names></name><name><surname>Bromet</surname><given-names>E</given-names></name></person-group><article-title>Substance use disorder and the early course of illness in schizophrenia and affective psychosis</article-title><source>Schizophr. Bull.</source><year>1997</year><volume>23</volume><fpage>195</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">9165630</pub-id></citation></ref><ref id="R102"><label>102</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kreitzer</surname><given-names>AC</given-names></name></person-group><article-title>Neurotransmission: emerging roles of endocannabinoids</article-title><source>Curr. Biol.</source><year>2005</year><volume>15</volume><fpage>R549</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">16051162</pub-id></citation></ref><ref id="R103"><label>103</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kunos</surname><given-names>G</given-names></name><name><surname>Batkai</surname><given-names>S</given-names></name><name><surname>Offertaler</surname><given-names>L</given-names></name><name><surname>Mo</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Karcher</surname><given-names>J</given-names></name><name><surname>Harvey-White</surname><given-names>J</given-names></name></person-group><article-title>The quest for a vascular endothelial cannabinoid receptor</article-title><source>Chem. Phys. Lipids</source><year>2002</year><volume>121</volume><fpage>45</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">12505689</pub-id></citation></ref><ref id="R104"><label>104</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lastres-Becker</surname><given-names>I</given-names></name><name><surname>Cebeira</surname><given-names>M</given-names></name><name><surname>de Ceballos</surname><given-names>ML</given-names></name><name><surname>Zeng</surname><given-names>BY</given-names></name><name><surname>Jenner</surname><given-names>P</given-names></name><name><surname>Ramos</surname><given-names>JA</given-names></name><name><surname>Fernandez-Ruiz</surname><given-names>JJ</given-names></name></person-group><article-title>Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets</article-title><source>Eur. J. Neurosci.</source><year>2001</year><volume>14</volume><fpage>1827</fpage><lpage>1832</lpage><pub-id pub-id-type="pmid">11860478</pub-id></citation></ref><ref id="R105"><label>105</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lastres-Becker</surname><given-names>I</given-names></name><name><surname>Molina-Holgado</surname><given-names>F</given-names></name><name><surname>Ramos</surname><given-names>JA</given-names></name><name><surname>Mechoulam</surname><given-names>R</given-names></name><name><surname>Fernandez-Ruiz</surname><given-names>J</given-names></name></person-group><article-title>Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease</article-title><source>Neurobiol. Dis.</source><year>2005</year><volume>19</volume><fpage>96</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">15837565</pub-id></citation></ref><ref id="R106"><label>106</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laviolette</surname><given-names>SR</given-names></name><name><surname>Grace</surname><given-names>AA</given-names></name></person-group><article-title>Cannabinoids potentiate emotional learning plasticity in neurons of the medial prefrontal cortex through basolateral amygdala inputs</article-title><source>J. Neurosci.</source><year>2006</year><volume>26</volume><fpage>6458</fpage><lpage>6468</lpage><pub-id pub-id-type="pmid">16775133</pub-id></citation></ref><ref id="R107"><label>107</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laviolette</surname><given-names>SR</given-names></name><name><surname>Grace</surname><given-names>AA</given-names></name></person-group><article-title>The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits implications for schizophrenia and addiction</article-title><source>Cell Mol. Life Sci.</source><year>2006</year><volume>63</volume><fpage>1597</fpage><lpage>1613</lpage><pub-id pub-id-type="pmid">16699809</pub-id></citation></ref><ref id="R108"><label>108</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Le Foll</surname><given-names>B</given-names></name><name><surname>Goldberg</surname><given-names>SR</given-names></name></person-group><article-title>Control of the reinforcing effects of nicotine by associated environmental stimuli in animals and humans</article-title><source>Trends Pharmacol. Sci.</source><year>2005</year><volume>26</volume><fpage>287</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">15925703</pub-id></citation></ref><ref id="R109"><label>109</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ledent</surname><given-names>C</given-names></name><name><surname>Valverde</surname><given-names>O</given-names></name><name><surname>Cossu</surname><given-names>G</given-names></name><name><surname>Petitet</surname><given-names>F</given-names></name><name><surname>Aubert</surname><given-names>JF</given-names></name><name><surname>Beslot</surname><given-names>F</given-names></name><name><surname>Bohme</surname><given-names>GA</given-names></name><name><surname>Imperato</surname><given-names>A</given-names></name><name><surname>Pedrazzini</surname><given-names>T</given-names></name><name><surname>Roques</surname><given-names>BP</given-names></name><name><surname>Vassart</surname><given-names>G</given-names></name><name><surname>Fratta</surname><given-names>W</given-names></name><name><surname>Parmentier</surname><given-names>M</given-names></name></person-group><article-title>Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice</article-title><source>Science</source><year>1999</year><volume>283</volume><fpage>401</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">9888857</pub-id></citation></ref><ref id="R110"><label>110</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leweke</surname><given-names>FM</given-names></name><name><surname>Giuffrida</surname><given-names>A</given-names></name><name><surname>Wurster</surname><given-names>U</given-names></name><name><surname>Emrich</surname><given-names>HM</given-names></name><name><surname>Piomelli</surname><given-names>D</given-names></name></person-group><article-title>Elevated endogenous cannabinoids in schizophrenia</article-title><source>Neuroreport</source><year>1999</year><volume>10</volume><fpage>1665</fpage><lpage>1669</lpage><pub-id pub-id-type="pmid">10501554</pub-id></citation></ref><ref id="R111"><label>111</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Linszen</surname><given-names>DH</given-names></name><name><surname>Dingemans</surname><given-names>PM</given-names></name><name><surname>Lenior</surname><given-names>ME</given-names></name></person-group><article-title>Cannabis abuse and the course of recent-onset schizophrenic disorders</article-title><source>Arch. Gen. Psychiatry</source><year>1994</year><volume>51</volume><fpage>273</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">8161287</pub-id></citation></ref><ref id="R112"><label>112</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lomo</surname><given-names>T</given-names></name></person-group><article-title>The discovery of long-term potentiation</article-title><source>Philos. Trans. R. Soc. Lond. B. Biol. Sci</source><year>2003</year><volume>358</volume><fpage>617</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">12740104</pub-id></citation></ref><ref id="R113"><label>113</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lotharius</surname><given-names>J</given-names></name><name><surname>Barg</surname><given-names>S</given-names></name><name><surname>Wiekop</surname><given-names>P</given-names></name><name><surname>Lundberg</surname><given-names>C</given-names></name><name><surname>Raymon</surname><given-names>HK</given-names></name><name><surname>Brundin</surname><given-names>P</given-names></name></person-group><article-title>Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line</article-title><source>J. Biol. Chem.</source><year>2002</year><volume>277</volume><fpage>38884</fpage><lpage>38894</lpage><pub-id pub-id-type="pmid">12145295</pub-id></citation></ref><ref id="R114"><label>114</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lupica</surname><given-names>CR</given-names></name><name><surname>Riegel</surname><given-names>AC</given-names></name></person-group><article-title>Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction</article-title><source>Neuropharmacology</source><year>2005</year><volume>48</volume><fpage>1105</fpage><lpage>1116</lpage><pub-id pub-id-type="pmid">15878779</pub-id></citation></ref><ref id="R115"><label>115</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maccarrone</surname><given-names>M</given-names></name><name><surname>Gubellini</surname><given-names>P</given-names></name><name><surname>Bari</surname><given-names>M</given-names></name><name><surname>Picconi</surname><given-names>B</given-names></name><name><surname>Battista</surname><given-names>N</given-names></name><name><surname>Centonze</surname><given-names>D</given-names></name><name><surname>Bernardi</surname><given-names>G</given-names></name><name><surname>Finazzi-Agro</surname><given-names>A</given-names></name><name><surname>Calabresi</surname><given-names>P</given-names></name></person-group><article-title>Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism</article-title><source>J. Neurochem.</source><year>2003</year><volume>85</volume><fpage>1018</fpage><lpage>1025</lpage><pub-id pub-id-type="pmid">12716433</pub-id></citation></ref><ref id="R116"><label>116</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mackie</surname><given-names>K</given-names></name></person-group><article-title>Distribution of cannabinoid receptors in the central and peripheral nervous system</article-title><source>Handb Exp. Pharmacol.</source><year>2005</year><fpage>299</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">16596779</pub-id></citation></ref><ref id="R117"><label>117</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mackie</surname><given-names>K</given-names></name><name><surname>Hille</surname><given-names>B</given-names></name></person-group><article-title>Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1992</year><volume>89</volume><fpage>3825</fpage><lpage>3829</lpage><pub-id pub-id-type="pmid">1315042</pub-id></citation></ref><ref id="R118"><label>118</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mackie</surname><given-names>K</given-names></name><name><surname>Lai</surname><given-names>Y</given-names></name><name><surname>Westenbroek</surname><given-names>R</given-names></name><name><surname>Mitchell</surname><given-names>R</given-names></name></person-group><article-title>Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor</article-title><source>J. Neurosci.</source><year>1995</year><volume>15</volume><fpage>6552</fpage><lpage>6561</lpage><pub-id pub-id-type="pmid">7472417</pub-id></citation></ref><ref id="R119"><label>119</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mailleux</surname><given-names>P</given-names></name><name><surname>Vanderhaeghen</surname><given-names>JJ</given-names></name></person-group><article-title>Age-related loss of cannabinoid receptor binding sites and mRNA in the rat striatum</article-title><source>Neurosci. Lett.</source><year>1992</year><volume>147</volume><fpage>179</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">1491804</pub-id></citation></ref><ref id="R120"><label>120</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mailleux</surname><given-names>P</given-names></name><name><surname>Vanderhaeghen</surname><given-names>JJ</given-names></name></person-group><article-title>Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen an in situ hybridization study</article-title><source>J. Neurochem.</source><year>1993</year><volume>61</volume><fpage>1705</fpage><lpage>1712</lpage><pub-id pub-id-type="pmid">7901331</pub-id></citation></ref><ref id="R121"><label>121</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mailleux</surname><given-names>P</given-names></name><name><surname>Verslijpe</surname><given-names>M</given-names></name><name><surname>Vanderhaeghen</surname><given-names>JJ</given-names></name></person-group><article-title>Initial observations on the distribution of cannabinoid receptor binding sites in the human adult basal ganglia using autoradiography</article-title><source>Neurosci. Lett.</source><year>1992</year><volume>139</volume><fpage>7</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1407683</pub-id></citation></ref><ref id="R122"><label>122</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Makara</surname><given-names>JK</given-names></name><name><surname>Mor</surname><given-names>M</given-names></name><name><surname>Fegley</surname><given-names>D</given-names></name><name><surname>Szabo</surname><given-names>SI</given-names></name><name><surname>Kathuria</surname><given-names>S</given-names></name><name><surname>Astarita</surname><given-names>G</given-names></name><name><surname>Duranti</surname><given-names>A</given-names></name><name><surname>Tontini</surname><given-names>A</given-names></name><name><surname>Tarzia</surname><given-names>G</given-names></name><name><surname>Rivara</surname><given-names>S</given-names></name><name><surname>Freund</surname><given-names>TF</given-names></name><name><surname>Piomelli</surname><given-names>D</given-names></name></person-group><article-title>Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus</article-title><source>Nat. Neurosci</source><year>2007</year><volume>10</volume><fpage>134</fpage></citation></ref><ref id="R123"><label>123</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maldonado</surname><given-names>R</given-names></name><name><surname>Rodriguez de Fonseca</surname><given-names>F</given-names></name></person-group><article-title>Cannabinoid addiction: behavioral models and neural correlates</article-title><source>J. Neurosci.</source><year>2002</year><volume>22</volume><fpage>3326</fpage><lpage>3331</lpage><pub-id pub-id-type="pmid">11978807</pub-id></citation></ref><ref id="R124"><label>124</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maldonado</surname><given-names>R</given-names></name><name><surname>Valverde</surname><given-names>O</given-names></name><name><surname>Berrendero</surname><given-names>F</given-names></name></person-group><article-title>Involvement of the endocannabinoid system in drug addiction</article-title><source>Trends Neurosci</source><year>2006</year><volume>29</volume><fpage>225</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">16483675</pub-id></citation></ref><ref id="R125"><label>125</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marinelli</surname><given-names>M</given-names></name><name><surname>Rudick</surname><given-names>CN</given-names></name><name><surname>Hu</surname><given-names>XT</given-names></name><name><surname>White</surname><given-names>FJ</given-names></name></person-group><article-title>Excitability of dopamine neurons: modulation and physiological consequences</article-title><source>CNS Neurol. Disord. Drug Targets</source><year>2006</year><volume>5</volume><fpage>79</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">16613555</pub-id></citation></ref><ref id="R126"><label>126</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marinelli</surname><given-names>S</given-names></name><name><surname>Di Marzo</surname><given-names>V</given-names></name><name><surname>Berretta</surname><given-names>N</given-names></name><name><surname>Matias</surname><given-names>I</given-names></name><name><surname>Maccarrone</surname><given-names>M</given-names></name><name><surname>Bernardi</surname><given-names>G</given-names></name><name><surname>Mercuri</surname><given-names>NB</given-names></name></person-group><article-title>Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors</article-title><source>J. Neurosci.</source><year>2003</year><volume>23</volume><fpage>3136</fpage><lpage>3144</lpage><pub-id pub-id-type="pmid">12716921</pub-id></citation></ref><ref id="R127"><label>127</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marinelli</surname><given-names>S</given-names></name><name><surname>Di Marzo</surname><given-names>V</given-names></name><name><surname>Florenzano</surname><given-names>F</given-names></name><name><surname>Fezza</surname><given-names>F</given-names></name><name><surname>Viscomi</surname><given-names>MT</given-names></name><name><surname>van der Stelt</surname><given-names>M</given-names></name><name><surname>Bernardi</surname><given-names>G</given-names></name><name><surname>Molinari</surname><given-names>M</given-names></name><name><surname>Maccarrone</surname><given-names>M</given-names></name><name><surname>Mercuri</surname><given-names>NB</given-names></name></person-group><article-title>N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors</article-title><source>Neuropsychopharmacology</source><year>2007</year><volume>32</volume><fpage>298</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">16760924</pub-id></citation></ref><ref id="R128"><label>128</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marsicano</surname><given-names>G</given-names></name><name><surname>Goodenough</surname><given-names>S</given-names></name><name><surname>Monory</surname><given-names>K</given-names></name><name><surname>Hermann</surname><given-names>H</given-names></name><name><surname>Eder</surname><given-names>M</given-names></name><name><surname>Cannich</surname><given-names>A</given-names></name><name><surname>Azad</surname><given-names>SC</given-names></name><name><surname>Cascio</surname><given-names>MG</given-names></name><name><surname>Gutierrez</surname><given-names>SO</given-names></name><name><surname>van der Stelt</surname><given-names>M</given-names></name><name><surname>Lopez-Rodriguez</surname><given-names>ML</given-names></name><name><surname>Casanova</surname><given-names>E</given-names></name><name><surname>Schutz</surname><given-names>G</given-names></name><name><surname>Zieglgansberger</surname><given-names>W</given-names></name><name><surname>Di Marzo</surname><given-names>V</given-names></name><name><surname>Behl</surname><given-names>C</given-names></name><name><surname>Lutz</surname><given-names>B</given-names></name></person-group><article-title>CB1 cannabinoid receptors and on-demand defense against excitotoxicity</article-title><source>Science</source><year>2003</year><volume>302</volume><fpage>84</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">14526074</pub-id></citation></ref><ref id="R129"><label>129</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marsicano</surname><given-names>G</given-names></name><name><surname>Lutz</surname><given-names>B</given-names></name></person-group><article-title>Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain</article-title><source>Eur. J. Neurosci.</source><year>1999</year><volume>11</volume><fpage>4213</fpage><lpage>4225</lpage><pub-id pub-id-type="pmid">10594647</pub-id></citation></ref><ref id="R130"><label>130</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marsicano</surname><given-names>G</given-names></name><name><surname>Lutz</surname><given-names>B</given-names></name></person-group><article-title>Neuromodulatory functions of the endocannabinoid system </article-title><source>J.Endocrinol. Invest.</source><year>2006</year><volume>29</volume><fpage>27</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">16751707</pub-id></citation></ref><ref id="R131"><label>131</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Massa</surname><given-names>F</given-names></name><name><surname>Storr</surname><given-names>M</given-names></name><name><surname>Lutz</surname><given-names>B</given-names></name></person-group><article-title>The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract</article-title><source>J. Mol. Med.</source><year>2005</year><volume>83</volume><fpage>944</fpage><lpage>954</lpage><pub-id pub-id-type="pmid">16133420</pub-id></citation></ref><ref id="R132"><label>132</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>LA</given-names></name><name><surname>Bonner</surname><given-names>TI</given-names></name><name><surname>Lolait</surname><given-names>SJ</given-names></name></person-group><article-title>Localization of cannabinoid receptor mRNA in rat brain</article-title><source>J. Comp. Neurol.</source><year>1993</year><volume>327</volume><fpage>535</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">8440779</pub-id></citation></ref><ref id="R133"><label>133</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mechoulam</surname><given-names>R</given-names></name><name><surname>Ben-Shabat</surname><given-names>S</given-names></name><name><surname>Hanus</surname><given-names>L</given-names></name><name><surname>Ligumsky</surname><given-names>M</given-names></name><name><surname>Kaminski</surname><given-names>NE</given-names></name><name><surname>Schatz</surname><given-names>AR</given-names></name><name><surname>Gopher</surname><given-names>A</given-names></name><name><surname>Almog</surname><given-names>S</given-names></name><name><surname>Martin</surname><given-names>BR</given-names></name><name><surname>Compton</surname><given-names>DR</given-names></name></person-group><article-title>Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors</article-title><source>Biochem. Pharmacol.</source><year>1995</year><volume>50</volume><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">7605349</pub-id></citation></ref><ref id="R134"><label>134</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mechoulam</surname><given-names>R</given-names></name><name><surname>Spatz</surname><given-names>M</given-names></name><name><surname>Shohami</surname><given-names>E</given-names></name></person-group><article-title>Endocannabinoids and neuroprotection</article-title><source>Sci. STKE</source><year>2002</year><volume>2002</volume><fpage>RE5</fpage><pub-id pub-id-type="pmid">11972360</pub-id></citation></ref><ref id="R135"><label>135</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mehler</surname><given-names>MF</given-names></name><name><surname>Gokhan</surname><given-names>S</given-names></name></person-group><article-title>Mechanisms underlying neural cell death in neurodegenerative diseases: alterations of a developmentally-mediated cellular rheostat</article-title><source>Trends Neurosci.</source><year>2000</year><volume>23</volume><fpage>599</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">11137149</pub-id></citation></ref><ref id="R136"><label>136</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Melis</surname><given-names>M</given-names></name><name><surname>Perra</surname><given-names>S</given-names></name><name><surname>Muntoni</surname><given-names>AL</given-names></name><name><surname>Pillolla</surname><given-names>G</given-names></name><name><surname>Lutz</surname><given-names>B</given-names></name><name><surname>Marsicano</surname><given-names>G</given-names></name><name><surname>Di Marzo</surname><given-names>V</given-names></name><name><surname>Gessa</surname><given-names>GL</given-names></name><name><surname>Pistis</surname><given-names>M</given-names></name></person-group><article-title>Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons</article-title><source>J. Neurosci</source><year>2004</year><volume>24</volume><fpage>10707</fpage><lpage>10715</lpage><pub-id pub-id-type="pmid">15564588</pub-id></citation></ref><ref id="R137"><label>137</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Melis</surname><given-names>M</given-names></name><name><surname>Pillolla</surname><given-names>G</given-names></name><name><surname>Bisogno</surname><given-names>T</given-names></name><name><surname>Minassi</surname><given-names>A</given-names></name><name><surname>Petrosino</surname><given-names>S</given-names></name><name><surname>Perra</surname><given-names>S</given-names></name><name><surname>Muntoni</surname><given-names>AL</given-names></name><name><surname>Lutz</surname><given-names>B</given-names></name><name><surname>Gessa</surname><given-names>GL</given-names></name><name><surname>Marsicano</surname><given-names>G</given-names></name><name><surname>Di Marzo</surname><given-names>V</given-names></name><name><surname>Pistis</surname><given-names>M</given-names></name></person-group><article-title>Protective activation of the endocannabinoid system during ischemia in dopamine neurons</article-title><source>Neurobiol. Dis.</source><year>2006</year><volume>24</volume><fpage>15</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">16762556</pub-id></citation></ref><ref id="R138"><label>138</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Melis</surname><given-names>M</given-names></name><name><surname>Pistis</surname><given-names>M</given-names></name><name><surname>Perra</surname><given-names>S</given-names></name><name><surname>Muntoni</surname><given-names>AL</given-names></name><name><surname>Pillolla</surname><given-names>G</given-names></name><name><surname>Gessa</surname><given-names>GL</given-names></name></person-group><article-title>Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors</article-title><source>J. Neurosci.</source><year>2004</year><volume>24</volume><fpage>53</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">14715937</pub-id></citation></ref><ref id="R139"><label>139</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meltzer</surname><given-names>LT</given-names></name><name><surname>Christoffersen</surname><given-names>CL</given-names></name><name><surname>Serpa</surname><given-names>KA</given-names></name></person-group><article-title>Modulation of dopamine neuronal activity by glutamate receptor subtypes</article-title><source>Neurosci. Biobehav. Rev</source><year>1997</year><volume>21</volume><fpage>511</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">9195610</pub-id></citation></ref><ref id="R140"><label>140</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meschler</surname><given-names>JP</given-names></name><name><surname>Conley</surname><given-names>TJ</given-names></name><name><surname>Howlett</surname><given-names>AC</given-names></name></person-group><article-title>Cannabinoid and dopamine interaction in rodent brain: effects on locomotor activity</article-title><source>Pharmacol. Biochem. Behav.</source><year>2000</year><volume>67</volume><fpage>567</fpage><lpage>573</lpage><pub-id pub-id-type="pmid">11164087</pub-id></citation></ref><ref id="R141"><label>141</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meschler</surname><given-names>JP</given-names></name><name><surname>Howlett</surname><given-names>AC</given-names></name><name><surname>Madras</surname><given-names>BK</given-names></name></person-group><article-title>Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates</article-title><source>Psychopharmacology (Berl.)</source><year>2001</year><volume>156</volume><fpage>79</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">11465637</pub-id></citation></ref><ref id="R142"><label>142</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Molina-Holgado</surname><given-names>F</given-names></name><name><surname>Lledo</surname><given-names>A</given-names></name><name><surname>Guaza</surname><given-names>C</given-names></name></person-group><article-title>Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes</article-title><source>Neurorepor</source><year>1997</year><volume>8</volume><fpage>1929</fpage><lpage>1933</lpage></citation></ref><ref id="R143"><label>143</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Monory</surname><given-names>K</given-names></name><name><surname>Massa</surname><given-names>F</given-names></name><name><surname>Egertova</surname><given-names>M</given-names></name><name><surname>Eder</surname><given-names>M</given-names></name><name><surname>Blaudzun</surname><given-names>H</given-names></name><name><surname>Westenbroek</surname><given-names>R</given-names></name><name><surname>Kelsch</surname><given-names>W</given-names></name><name><surname>Jacob</surname><given-names>W</given-names></name><name><surname>Marsch</surname><given-names>R</given-names></name><name><surname>Ekker</surname><given-names>M</given-names></name><name><surname>Long</surname><given-names>J</given-names></name><name><surname>Rubenstein</surname><given-names>JL</given-names></name><name><surname>Goebbels</surname><given-names>S</given-names></name><name><surname>Nave</surname><given-names>KA</given-names></name><name><surname>During</surname><given-names>M</given-names></name><name><surname>Klugmann</surname><given-names>M</given-names></name><name><surname>Wolfel</surname><given-names>B</given-names></name><name><surname>Dodt</surname><given-names>HU</given-names></name><name><surname>Zieglgansberger</surname><given-names>W</given-names></name><name><surname>Wotjak</surname><given-names>CT</given-names></name><name><surname>Mackie</surname><given-names>K</given-names></name><name><surname>Elphick</surname><given-names>MR</given-names></name><name><surname>Marsicano</surname><given-names>G</given-names></name><name><surname>Lutz</surname><given-names>B</given-names></name></person-group><article-title>The endocannabinoid system controls key epileptogenic circuits in the hippocampus</article-title><source>Neuron</source><year>2006</year><volume>51</volume><fpage>455</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">16908411</pub-id></citation></ref><ref id="R144"><label>144</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Munro</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>KL</given-names></name><name><surname>Abu-Shaar</surname><given-names>M</given-names></name></person-group><article-title>Molecular characterization of a peripheral receptor for cannabinoids</article-title><source>Nature</source><year>1993</year><volume>365</volume><fpage>61</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">7689702</pub-id></citation></ref><ref id="R145"><label>145</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nagayama</surname><given-names>T</given-names></name><name><surname>Sinor</surname><given-names>AD</given-names></name><name><surname>Simon</surname><given-names>RP</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Graham</surname><given-names>SH</given-names></name><name><surname>Jin</surname><given-names>K</given-names></name><name><surname>Greenberg</surname><given-names>DA</given-names></name></person-group><article-title>Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures</article-title><source>J. Neurosci.</source><year>1999</year><volume>19</volume><fpage>2987</fpage><lpage>2995</lpage><pub-id pub-id-type="pmid">10191316</pub-id></citation></ref><ref id="R146"><label>146</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>Carrera</surname><given-names>MR</given-names></name><name><surname>Fratta</surname><given-names>W</given-names></name><name><surname>Valverde</surname><given-names>O</given-names></name><name><surname>Cossu</surname><given-names>G</given-names></name><name><surname>Fattore</surname><given-names>L</given-names></name><name><surname>Chowen</surname><given-names>JA</given-names></name><name><surname>Gomez</surname><given-names>R</given-names></name><name><surname>del Arco</surname><given-names>I</given-names></name><name><surname>Villanua</surname><given-names>MA</given-names></name><name><surname>Maldonado</surname><given-names>R</given-names></name><name><surname>Koob</surname><given-names>GF</given-names></name><name><surname>Rodriguez de Fonseca</surname><given-names>F</given-names></name></person-group><article-title>Functional interaction between opioid and cannabinoid receptors in drug self-administration</article-title><source>J. Neurosci.</source><year>2001</year><volume>21</volume><fpage>5344</fpage><lpage>5350</lpage><pub-id pub-id-type="pmid">11438610</pub-id></citation></ref><ref id="R147"><label>147</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okamoto</surname><given-names>Y</given-names></name><name><surname>Morishita</surname><given-names>J</given-names></name><name><surname>Tsuboi</surname><given-names>K</given-names></name><name><surname>Tonai</surname><given-names>T</given-names></name><name><surname>Ueda</surname><given-names>N</given-names></name></person-group><article-title>Molecular characterization of a phospholipase D generating anandamide and its congeners</article-title><source>J. Biol. Chem</source><year>2004</year><volume>279</volume><fpage>5298</fpage><lpage>5305</lpage><pub-id pub-id-type="pmid">14634025</pub-id></citation></ref><ref id="R148"><label>148</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Onaivi</surname><given-names>ES</given-names></name><name><surname>Ishiguro</surname><given-names>H</given-names></name><name><surname>Gong</surname><given-names>JP</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Perchuk</surname><given-names>A</given-names></name><name><surname>Meozzi</surname><given-names>PA</given-names></name><name><surname>Myers</surname><given-names>L</given-names></name><name><surname>Mora</surname><given-names>Z</given-names></name><name><surname>Tagliaferro</surname><given-names>P</given-names></name><name><surname>Gardner</surname><given-names>E</given-names></name><name><surname>Brusco</surname><given-names>A</given-names></name><name><surname>Akinshola</surname><given-names>BE</given-names></name><name><surname>Liu</surname><given-names>QR</given-names></name><name><surname>Hope</surname><given-names>B</given-names></name><name><surname>Iwasaki</surname><given-names>S</given-names></name><name><surname>Arinami</surname><given-names>T</given-names></name><name><surname>Teasenfitz</surname><given-names>L</given-names></name><name><surname>Uhl</surname><given-names>GR</given-names></name></person-group><article-title>Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2006</year><volume>1074</volume><fpage>514</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">17105950</pub-id></citation></ref><ref id="R149"><label>149</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Overton</surname><given-names>P</given-names></name><name><surname>Clark</surname><given-names>D</given-names></name></person-group><article-title>N-methyl-D-aspartate increases the excitability of nigrostriatal dopamine terminals</article-title><source>Eur. J. Pharmacol.</source><year>1991</year><volume>201</volume><fpage>117</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">1794413</pub-id></citation></ref><ref id="R150"><label>150</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Overton</surname><given-names>P</given-names></name><name><surname>Clark</surname><given-names>D</given-names></name></person-group><article-title>Iontophoretically administered drugs acting at the N-methyl-D-aspartate receptor modulate burst firing in A9 dopamine neurons in the rat</article-title><source>Synapse</source><year>1992</year><volume>10</volume><fpage>131</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">1533955</pub-id></citation></ref><ref id="R151"><label>151</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pacher</surname><given-names>P</given-names></name><name><surname>Batkai</surname><given-names>S</given-names></name><name><surname>Kunos</surname><given-names>G</given-names></name></person-group><article-title>The endocannabinoid system as an emerging target of pharmacotherapy</article-title><source>Pharmacol. Rev.</source><year>2006</year><volume>58</volume><fpage>389</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">16968947</pub-id></citation></ref><ref id="R152"><label>152</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Panikashvili</surname><given-names>D</given-names></name><name><surname>Simeonidou</surname><given-names>C</given-names></name><name><surname>Ben-Shabat</surname><given-names>S</given-names></name><name><surname>Hanus</surname><given-names>L</given-names></name><name><surname>Breuer</surname><given-names>A</given-names></name><name><surname>Mechoulam</surname><given-names>R</given-names></name><name><surname>Shohami</surname><given-names>E</given-names></name></person-group><article-title>An endogenous cannabinoid (2-AG) is neuroprotective after brain injury</article-title><source>Nature</source><year>2001</year><volume>413</volume><fpage>527</fpage><lpage>531</lpage><pub-id pub-id-type="pmid">11586361</pub-id></citation></ref><ref id="R153"><label>153</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paradisi</surname><given-names>A</given-names></name><name><surname>Oddi</surname><given-names>S</given-names></name><name><surname>Maccarrone</surname><given-names>M</given-names></name></person-group><article-title>The endocannabinoid system in ageing: a new target for drug development</article-title><source>Curr. Drug Targets</source><year>2006</year><volume>7</volume><fpage>1539</fpage><lpage>1552</lpage><pub-id pub-id-type="pmid">17100593</pub-id></citation></ref><ref id="R154"><label>154</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parmentier-Batteur</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>K</given-names></name><name><surname>Mao</surname><given-names>XO</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Greenberg</surname><given-names>DA</given-names></name></person-group><article-title>Increased severity of stroke in CB1 cannabinoid receptor knock-out mice</article-title><source>J. Neurosci.</source><year>2002</year><volume>22</volume><fpage>9771</fpage><lpage>9775</lpage><pub-id pub-id-type="pmid">12427832</pub-id></citation></ref><ref id="R155"><label>155</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perra</surname><given-names>S</given-names></name><name><surname>Pillolla</surname><given-names>G</given-names></name><name><surname>Melis</surname><given-names>M</given-names></name><name><surname>Muntoni</surname><given-names>AL</given-names></name><name><surname>Gessa</surname><given-names>GL</given-names></name><name><surname>Pistis</surname><given-names>M</given-names></name></person-group><article-title>Involvement of the endogenous cannabinoid system in the effects of alcohol in the mesolimbic reward circuit: electrophysiological evidence <italic>in vivo</italic></article-title><source>Psychopharmacology (Berl.)</source><year>2005</year><volume>183</volume><fpage>368</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">16228194</pub-id></citation></ref><ref id="R156"><label>156</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piomelli</surname><given-names>D</given-names></name></person-group><article-title>The molecular logic of endocannabinoid signalling </article-title><source>Nat.Rev. Neurosci.</source><year>2003</year><volume>4</volume><fpage>873</fpage><lpage>884</lpage><pub-id pub-id-type="pmid">14595399</pub-id></citation></ref><ref id="R157"><label>157</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pisani</surname><given-names>A</given-names></name><name><surname>Fezza</surname><given-names>F</given-names></name><name><surname>Galati</surname><given-names>S</given-names></name><name><surname>Battista</surname><given-names>N</given-names></name><name><surname>Napolitano</surname><given-names>S</given-names></name><name><surname>Finazzi-Agro</surname><given-names>A</given-names></name><name><surname>Bernardi</surname><given-names>G</given-names></name><name><surname>Brusa</surname><given-names>L</given-names></name><name><surname>Pierantozzi</surname><given-names>M</given-names></name><name><surname>Stanzione</surname><given-names>P</given-names></name><name><surname>Maccarrone</surname><given-names>M</given-names></name></person-group><article-title>High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients</article-title><source>Ann. Neurol.</source><year>2005</year><volume>57</volume><fpage>777</fpage><lpage>779</lpage><pub-id pub-id-type="pmid">15852389</pub-id></citation></ref><ref id="R158"><label>158</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pistis</surname><given-names>M</given-names></name><name><surname>Ferraro</surname><given-names>L</given-names></name><name><surname>Pira</surname><given-names>L</given-names></name><name><surname>Flore</surname><given-names>G</given-names></name><name><surname>Tanganelli</surname><given-names>S</given-names></name><name><surname>Gessa</surname><given-names>GL</given-names></name><name><surname>Devoto</surname><given-names>P</given-names></name></person-group><article-title>Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex an in vivo microdialysis study</article-title><source>Brain Res</source><year>2002</year><volume>948</volume><fpage>155</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">12383968</pub-id></citation></ref><ref id="R159"><label>159</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pistis</surname><given-names>M</given-names></name><name><surname>Perra</surname><given-names>S</given-names></name><name><surname>Pillolla</surname><given-names>G</given-names></name><name><surname>Melis</surname><given-names>M</given-names></name><name><surname>Muntoni</surname><given-names>AL</given-names></name><name><surname>Gessa</surname><given-names>GL</given-names></name></person-group><article-title>Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons</article-title><source>Biol. Psychiatry</source><year>2004</year><volume>56</volume><fpage>86</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">15231440</pub-id></citation></ref><ref id="R160"><label>160</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Redgrave</surname><given-names>P</given-names></name><name><surname>Gurney</surname><given-names>K</given-names></name></person-group><article-title>The short-latency dopamine signal a role in discovering novel actions?</article-title><source>Nat. Rev. Neurosci</source><year>2006</year><volume>7</volume><fpage>967</fpage><lpage>975</lpage><pub-id pub-id-type="pmid">17115078</pub-id></citation></ref><ref id="R161"><label>161</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riegel</surname><given-names>AC</given-names></name><name><surname>Lupica</surname><given-names>CR</given-names></name></person-group><article-title>Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area</article-title><source>J. Neurosci.</source><year>2004</year><volume>24</volume><fpage>11070</fpage><lpage>11078</lpage><pub-id pub-id-type="pmid">15590923</pub-id></citation></ref><ref id="R162"><label>162</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robbe</surname><given-names>D</given-names></name><name><surname>Alonso</surname><given-names>G</given-names></name><name><surname>Manzoni</surname><given-names>OJ</given-names></name></person-group><article-title>Exogenous and endogenous cannabinoids control synaptic transmission in mice nucleus accumbens</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2003</year><volume>1003</volume><fpage>212</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">14684448</pub-id></citation></ref><ref id="R163"><label>163</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robbe</surname><given-names>D</given-names></name><name><surname>Kopf</surname><given-names>M</given-names></name><name><surname>Remaury</surname><given-names>A</given-names></name><name><surname>Bockaert</surname><given-names>J</given-names></name><name><surname>Manzoni</surname><given-names>OJ</given-names></name></person-group><article-title>Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2002</year><volume>99</volume><fpage>8384</fpage><lpage>8388</lpage><pub-id pub-id-type="pmid">12060781</pub-id></citation></ref><ref id="R164"><label>164</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>TE</given-names></name><name><surname>Berridge</surname><given-names>KC</given-names></name></person-group><article-title>Addiction</article-title><source>Annu. Rev. Psychol</source><year>2003</year><volume>54</volume><fpage>25</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">12185211</pub-id></citation></ref><ref id="R165"><label>165</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez de Fonseca</surname><given-names>F</given-names></name><name><surname>Del Arco</surname><given-names>I</given-names></name><name><surname>Bermudez-Silva</surname><given-names>FJ</given-names></name><name><surname>Bilbao</surname><given-names>A</given-names></name><name><surname>Cippitelli</surname><given-names>A</given-names></name><name><surname>Navarro</surname><given-names>M</given-names></name></person-group><article-title>The endocannabinoid system: physiology and pharmacology</article-title><source>Alcohol Alcohol</source><year>2005</year><volume>40</volume><fpage>2</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">15550444</pub-id></citation></ref><ref id="R166"><label>166</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roitman</surname><given-names>MF</given-names></name><name><surname>Stuber</surname><given-names>GD</given-names></name><name><surname>Phillips</surname><given-names>PE</given-names></name><name><surname>Wightman</surname><given-names>RM</given-names></name><name><surname>Carelli</surname><given-names>RM</given-names></name></person-group><article-title>Dopamine operates as a subsecond modulator of food seeking</article-title><source>J. Neurosci.</source><year>2004</year><volume>24</volume><fpage>1265</fpage><lpage>1271</lpage><pub-id pub-id-type="pmid">14960596</pub-id></citation></ref><ref id="R167"><label>167</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>J</given-names></name><name><surname>Berrendero</surname><given-names>F</given-names></name><name><surname>Garcia-Gil</surname><given-names>L</given-names></name><name><surname>de la Cruz</surname><given-names>P</given-names></name><name><surname>Ramos</surname><given-names>JA</given-names></name><name><surname>Fernandez-Ruiz</surname><given-names>JJ</given-names></name></person-group><article-title>Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist-stimulated [35S]guanylyl-5'O-(thio)-triphosphate binding in the basal ganglia of aged rats</article-title><source>Neuroscience</source><year>1998</year><volume>84</volume><fpage>1075</fpage><lpage>1083</lpage><pub-id pub-id-type="pmid">9578396</pub-id></citation></ref><ref id="R168"><label>168</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>J</given-names></name><name><surname>Berrendero</surname><given-names>F</given-names></name><name><surname>Perez-Rosado</surname><given-names>A</given-names></name><name><surname>Manzanares</surname><given-names>J</given-names></name><name><surname>Rojo</surname><given-names>A</given-names></name><name><surname>Fernandez-Ruiz</surname><given-names>JJ</given-names></name><name><surname>de Yebenes</surname><given-names>JG</given-names></name><name><surname>Ramos</surname><given-names>JA</given-names></name></person-group><article-title>Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen</article-title><source>Life Sci.</source><year>2000</year><volume>66</volume><fpage>485</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">10794065</pub-id></citation></ref><ref id="R169"><label>169</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>J</given-names></name><name><surname>Garcia</surname><given-names>L</given-names></name><name><surname>Cebeira</surname><given-names>M</given-names></name><name><surname>Zadrozny</surname><given-names>D</given-names></name><name><surname>Fernandez-Ruiz</surname><given-names>JJ</given-names></name><name><surname>Ramos</surname><given-names>JA</given-names></name></person-group><article-title>The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior role of nigrostriatal dopaminergic neurons</article-title><source>Life Sci.</source><year>1995</year><volume>56</volume><fpage>2033</fpage><lpage>2040</lpage><pub-id pub-id-type="pmid">7776829</pub-id></citation></ref><ref id="R170"><label>170</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>J</given-names></name><name><surname>Lastres-Becker</surname><given-names>I</given-names></name><name><surname>de Miguel</surname><given-names>R</given-names></name><name><surname>Berrendero</surname><given-names>F</given-names></name><name><surname>Ramos</surname><given-names>JA</given-names></name><name><surname>Fernandez-Ruiz</surname><given-names>J</given-names></name></person-group><article-title>The endogenous cannabinoid system and the basal ganglia</article-title><source>Pharmacol. Ther</source><year>2002</year><volume>95</volume><fpage>137</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">12182961</pub-id></citation></ref><ref id="R171"><label>171</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rueda</surname><given-names>D</given-names></name><name><surname>Galve-Roperh</surname><given-names>I</given-names></name><name><surname>Haro</surname><given-names>A</given-names></name><name><surname>Guzman</surname><given-names>M</given-names></name></person-group><article-title>The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase</article-title><source>Mol. Pharmacol.</source><year>2000</year><volume>58</volume><fpage>814</fpage><lpage>820</lpage><pub-id pub-id-type="pmid">10999952</pub-id></citation></ref><ref id="R172"><label>172</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rueda</surname><given-names>D</given-names></name><name><surname>Navarro</surname><given-names>B</given-names></name><name><surname>Martinez-Serrano</surname><given-names>A</given-names></name><name><surname>Guzman</surname><given-names>M</given-names></name><name><surname>Galve-Roperh</surname><given-names>I</given-names></name></person-group><article-title>The endocannabinoid anandamide inhibits neuronal progenitor cell differentiation through attenuation of the Rap1/B-Raf/ERK pathway</article-title><source>J. Biol. Chem.</source><year>2002</year><volume>277</volume><fpage>46645</fpage><lpage>46650</lpage><pub-id pub-id-type="pmid">12237305</pub-id></citation></ref><ref id="R173"><label>173</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saal</surname><given-names>D</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Bonci</surname><given-names>A</given-names></name><name><surname>Malenka</surname><given-names>RC</given-names></name></person-group><article-title>Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons</article-title><source>Neuron</source><year>2003</year><volume>37</volume><fpage>577</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">12597856</pub-id></citation></ref><ref id="R174"><label>174</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saario</surname><given-names>SM</given-names></name><name><surname>Salo</surname><given-names>OM</given-names></name><name><surname>Nevalainen</surname><given-names>T</given-names></name><name><surname>Poso</surname><given-names>A</given-names></name><name><surname>Laitinen</surname><given-names>JT</given-names></name><name><surname>Jarvinen</surname><given-names>T</given-names></name><name><surname>Niemi</surname><given-names>R</given-names></name></person-group><article-title>Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes</article-title><source>Chem. Biol.</source><year>2005</year><volume>12</volume><fpage>649</fpage><lpage>656</lpage><pub-id pub-id-type="pmid">15975510</pub-id></citation></ref><ref id="R175"><label>175</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Safo</surname><given-names>PK</given-names></name><name><surname>Cravatt</surname><given-names>BF</given-names></name><name><surname>Regehr</surname><given-names>WG</given-names></name></person-group><article-title>Retrograde endocannabinoid signaling in the cerebellar cortex</article-title><source>Cerebellum</source><year>2006</year><volume>5</volume><fpage>134</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">16818388</pub-id></citation></ref><ref id="R176"><label>176</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanchis-Segura</surname><given-names>C</given-names></name><name><surname>Cline</surname><given-names>BH</given-names></name><name><surname>Marsicano</surname><given-names>G</given-names></name><name><surname>Lutz</surname><given-names>B</given-names></name><name><surname>Spanagel</surname><given-names>R</given-names></name></person-group><article-title>Reduced sensitivity to reward in CB1 knockout mice</article-title><source>Psychopharmacology(Berl.)</source><year>2004</year><volume>176</volume><fpage>223</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">15083252</pub-id></citation></ref><ref id="R177"><label>177</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schlicker</surname><given-names>E</given-names></name><name><surname>Kathmann</surname><given-names>M</given-names></name></person-group><article-title>Modulation of transmitter release via presynaptic cannabinoid receptors</article-title><source>Trends Pharmacol. Sci.</source><year>2001</year><volume>22</volume><fpage>565</fpage><lpage>572</lpage><pub-id pub-id-type="pmid">11698100</pub-id></citation></ref><ref id="R178"><label>178</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>U</given-names></name><name><surname>Leweke</surname><given-names>FM</given-names></name><name><surname>Mueller-Vahl</surname><given-names>KR</given-names></name><name><surname>Emrich</surname><given-names>HM</given-names></name></person-group><article-title>Cannabinoid/anandamide system and schizophrenia is there evidence for association?</article-title><source>Pharmacopsychiatry</source><year>1998</year><volume>31</volume><issue>Suppl. 2</issue><fpage>110</fpage><lpage>113</lpage></citation></ref><ref id="R179"><label>179</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schultz</surname><given-names>W</given-names></name></person-group><article-title>Predictive reward signal of dopamine neurons</article-title><source> J.Neurophysiol.</source><year>1998</year><volume>80</volume><fpage>1</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">9658025</pub-id></citation></ref><ref id="R180"><label>180</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schultz</surname><given-names>W</given-names></name></person-group><article-title>Getting formal with dopamine and reward</article-title><source>Neuron</source><year>2002</year><volume>36</volume><fpage>241</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">12383780</pub-id></citation></ref><ref id="R181"><label>181</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schultz</surname><given-names>W</given-names></name></person-group><article-title>Behavioral theories and the neurophysiology of reward </article-title><source>Annu.Rev. Psychol.</source><year>2006</year><volume>57</volume><fpage>87</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">16318590</pub-id></citation></ref><ref id="R182"><label>182</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schultz</surname><given-names>W</given-names></name><name><surname>Dickinson</surname><given-names>A</given-names></name></person-group><article-title>Neuronal coding of prediction errors</article-title><source>Annu. Rev. Neurosci.</source><year>2000</year><volume>23</volume><fpage>473</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">10845072</pub-id></citation></ref><ref id="R183"><label>183</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schwarting</surname><given-names>RK</given-names></name><name><surname>Huston</surname><given-names>JP</given-names></name></person-group><article-title>Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae</article-title><source>Prog. Neurobiol.</source><year>1996</year><volume>49</volume><fpage>215</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">8878304</pub-id></citation></ref><ref id="R184"><label>184</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>M</given-names></name><name><surname>Thayer</surname><given-names>SA</given-names></name></person-group><article-title>Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity</article-title><source>Mol. Pharmacol.</source><year>1998</year><volume>54</volume><fpage>459</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">9730904</pub-id></citation></ref><ref id="R185"><label>185</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shohami</surname><given-names>E</given-names></name><name><surname>Mechoulam</surname><given-names>R</given-names></name></person-group><article-title>Multiple sclerosis may disrupt endocannabinoid brain protection mechanism</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2006</year><volume>103</volume><fpage>6087</fpage><lpage>6088</lpage><pub-id pub-id-type="pmid">16606822</pub-id></citation></ref><ref id="R186"><label>186</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shouman</surname><given-names>B</given-names></name><name><surname>Fontaine</surname><given-names>RH</given-names></name><name><surname>Baud</surname><given-names>O</given-names></name><name><surname>Schwendimann</surname><given-names>L</given-names></name><name><surname>Keller</surname><given-names>M</given-names></name><name><surname>Spedding</surname><given-names>M</given-names></name><name><surname>Lelievre</surname><given-names>V</given-names></name><name><surname>Gressens</surname><given-names>P</given-names></name></person-group><article-title>Endocannabinoids potently protect the newborn brain against AMPA-kainate receptor-mediated excitotoxic damage</article-title><source>Br. J. Pharmacol.</source><year>2006</year><volume>148</volume><fpage>442</fpage><lpage>451</lpage><pub-id pub-id-type="pmid">16682966</pub-id></citation></ref><ref id="R187"><label>187</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Silverdale</surname><given-names>MA</given-names></name><name><surname>McGuire</surname><given-names>S</given-names></name><name><surname>McInnes</surname><given-names>A</given-names></name><name><surname>Crossman</surname><given-names>AR</given-names></name><name><surname>Brotchie</surname><given-names>JM</given-names></name></person-group><article-title>Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease</article-title><source>Exp. Neurol.</source><year>2001</year><volume>169</volume><fpage>400</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">11358453</pub-id></citation></ref><ref id="R188"><label>188</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sinor</surname><given-names>AD</given-names></name><name><surname>Irvin</surname><given-names>SM</given-names></name><name><surname>Greenberg</surname><given-names>DA</given-names></name></person-group><article-title>Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats</article-title><source>Neurosci. Lett.</source><year>2000</year><volume>278</volume><fpage>157</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">10653017</pub-id></citation></ref><ref id="R189"><label>189</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>AD</given-names></name><name><surname>Bolam</surname><given-names>JP</given-names></name></person-group><article-title>The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones</article-title><source>Trends Neurosci.</source><year>1990</year><volume>13</volume><fpage>259</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">1695400</pub-id></citation></ref><ref id="R190"><label>190</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Somogyi</surname><given-names>P</given-names></name><name><surname>Bolam</surname><given-names>JP</given-names></name><name><surname>Totterdell</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>AD</given-names></name></person-group><article-title>Monosynaptic input from the nucleus accumbens--ventral striatum region to retrogradely labelled nigrostriatal neurones</article-title><source>Brain Res.</source><year>1981</year><volume>217</volume><fpage>245</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">7248789</pub-id></citation></ref><ref id="R191"><label>191</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spano</surname><given-names>MS</given-names></name><name><surname>Fattore</surname><given-names>L</given-names></name><name><surname>Cossu</surname><given-names>G</given-names></name><name><surname>Deiana</surname><given-names>S</given-names></name><name><surname>Fadda</surname><given-names>P</given-names></name><name><surname>Fratta</surname><given-names>W</given-names></name></person-group><article-title>CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat</article-title><source>Br. J. Pharmacol.</source><year>2004</year><volume>143</volume><fpage>343</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">15339858</pub-id></citation></ref><ref id="R192"><label>192</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stamford</surname><given-names>JA</given-names></name></person-group><article-title>Development and ageing of the rat nigrostriatal dopamine system studied with fast cyclic voltammetry</article-title><source>J. Neurochem.</source><year>1989</year><volume>52</volume><fpage>1582</fpage><lpage>1589</lpage><pub-id pub-id-type="pmid">2709014</pub-id></citation></ref><ref id="R193"><label>193</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stella</surname><given-names>N</given-names></name><name><surname>Piomelli</surname><given-names>D</given-names></name></person-group><article-title>Receptor-dependent formation of endogenous cannabinoids in cortical neurons</article-title><source> Eur.J. Pharmacol.</source><year>2001</year><volume>425</volume><fpage>189</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">11513837</pub-id></citation></ref><ref id="R194"><label>194</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stella</surname><given-names>N</given-names></name><name><surname>Schweitzer</surname><given-names>P</given-names></name><name><surname>Piomelli</surname><given-names>D</given-names></name></person-group><article-title>A second endogenous cannabinoid that modulates long-term potentiation</article-title><source>Nature</source><year>1997</year><volume>388</volume><fpage>773</fpage><lpage>778</lpage><pub-id pub-id-type="pmid">9285589</pub-id></citation></ref><ref id="R195"><label>195</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sugiura</surname><given-names>T</given-names></name><name><surname>Kondo</surname><given-names>S</given-names></name><name><surname>Sukagawa</surname><given-names>A</given-names></name><name><surname>Nakane</surname><given-names>S</given-names></name><name><surname>Shinoda</surname><given-names>A</given-names></name><name><surname>Itoh</surname><given-names>K</given-names></name><name><surname>Yamashita</surname><given-names>A</given-names></name><name><surname>Waku</surname><given-names>K</given-names></name></person-group><article-title>2-Arachidonoylglycerol a possible endogenous cannabinoid receptor ligand in brain </article-title><source>Biochem.Biophys. Res. Commun</source><year>1995</year><volume>215</volume><fpage>89</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">7575630</pub-id></citation></ref><ref id="R196"><label>196</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sugiura</surname><given-names>T</given-names></name><name><surname>Waku</surname><given-names>K</given-names></name></person-group><article-title>2-arachidonoylglycerol: a possible multifunctional lipid mediator in the nervous and immune systems</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2000</year><volume>905</volume><fpage>344</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">10818479</pub-id></citation></ref><ref id="R197"><label>197</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szabo</surname><given-names>B</given-names></name><name><surname>Siemes</surname><given-names>S</given-names></name><name><surname>Wallmichrath</surname><given-names>I</given-names></name></person-group><article-title>Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids</article-title><source>Eur. J. Neurosci.</source><year>2002</year><volume>15</volume><fpage>2057</fpage><lpage>2061</lpage><pub-id pub-id-type="pmid">12099913</pub-id></citation></ref><ref id="R198"><label>198</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanda</surname><given-names>G</given-names></name><name><surname>Pontieri</surname><given-names>FE</given-names></name><name><surname>Di Chiara</surname><given-names>G</given-names></name></person-group><article-title>Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism</article-title><source>Science</source><year>1997</year><volume>276</volume><fpage>2048</fpage><lpage>2050</lpage><pub-id pub-id-type="pmid">9197269</pub-id></citation></ref><ref id="R199"><label>199</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Teicher</surname><given-names>MH</given-names></name><name><surname>Andersen</surname><given-names>SL</given-names></name><name><surname>Hostetter JC</surname><given-names>Jr</given-names></name></person-group><article-title>Evidence for dopamine receptor pruning between adolescence and adulthood in striatum but not nucleus accumbens</article-title><source>Brain Res. Dev. Brain Res.</source><year>1995</year><volume>89</volume><fpage>167</fpage><lpage>172</lpage></citation></ref><ref id="R200"><label>200</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Twitchell</surname><given-names>W</given-names></name><name><surname>Brown</surname><given-names>S</given-names></name><name><surname>Mackie</surname><given-names>K</given-names></name></person-group><article-title>Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons</article-title><source>J. Neurophysiol.</source><year>1997</year><volume>78</volume><fpage>43</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">9242259</pub-id></citation></ref><ref id="R201"><label>201</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ueda</surname><given-names>N</given-names></name><name><surname>Puffenbarger</surname><given-names>RA</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Deutsch</surname><given-names>DG</given-names></name></person-group><article-title>The fatty acid amide hydrolase (FAAH)</article-title><source>Chem. Phys. Lipids</source><year>2000</year><volume>108</volume><fpage>107</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">11106785</pub-id></citation></ref><ref id="R202"><label>202</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ungless</surname><given-names>MA</given-names></name><name><surname>Whistler</surname><given-names>JL</given-names></name><name><surname>Malenka</surname><given-names>RC</given-names></name><name><surname>Bonci</surname><given-names>A</given-names></name></person-group><article-title>Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons</article-title><source>Nature</source><year>2001</year><volume>411</volume><fpage>583</fpage><lpage>587</lpage><pub-id pub-id-type="pmid">11385572</pub-id></citation></ref><ref id="R203"><label>203</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van der Stelt</surname><given-names>M</given-names></name><name><surname>Di Marzo</surname><given-names>V</given-names></name></person-group><article-title>The endocannabinoid system in the basal ganglia and in the mesolimbic reward system implications for neurological and psychiatric disorders</article-title><source>Eur. J. Pharmacol</source><year>2003</year><volume>480</volume><fpage>133</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">14623357</pub-id></citation></ref><ref id="R204"><label>204</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van der Stelt</surname><given-names>M</given-names></name><name><surname>Veldhuis</surname><given-names>WB</given-names></name><name><surname>Bar</surname><given-names>PR</given-names></name><name><surname>Veldink</surname><given-names>GA</given-names></name><name><surname>Vliegenthart</surname><given-names>JF</given-names></name><name><surname>Nicolay</surname><given-names>K</given-names></name></person-group><article-title>Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced <italic>in vivo</italic> excitotoxicity</article-title><source>J. Neurosci.</source><year>2001</year><volume>21</volume><fpage>6475</fpage><lpage>6479</lpage><pub-id pub-id-type="pmid">11517236</pub-id></citation></ref><ref id="R205"><label>205</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van der Stelt</surname><given-names>M</given-names></name><name><surname>Veldhuis</surname><given-names>WB</given-names></name><name><surname>van Haaften</surname><given-names>GW</given-names></name><name><surname>Fezza</surname><given-names>F</given-names></name><name><surname>Bisogno</surname><given-names>T</given-names></name><name><surname>Bar</surname><given-names>PR</given-names></name><name><surname>Veldink</surname><given-names>GA</given-names></name><name><surname>Vliegenthart</surname><given-names>JF</given-names></name><name><surname>Di Marzo</surname><given-names>V</given-names></name><name><surname>Nicolay</surname><given-names>K</given-names></name></person-group><article-title>Exogenous anandamide protects rat brain against acute neuronal injury <italic>in vivo</italic></article-title><source>J. Neurosci.</source><year>2001</year><volume>21</volume><fpage>8765</fpage><lpage>8771</lpage><pub-id pub-id-type="pmid">11698588</pub-id></citation></ref><ref id="R206"><label>206</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Sickle</surname><given-names>MD</given-names></name><name><surname>Duncan</surname><given-names>M</given-names></name><name><surname>Kingsley</surname><given-names>PJ</given-names></name><name><surname>Mouihate</surname><given-names>A</given-names></name><name><surname>Urbani</surname><given-names>P</given-names></name><name><surname>Mackie</surname><given-names>K</given-names></name><name><surname>Stella</surname><given-names>N</given-names></name><name><surname>Makriyannis</surname><given-names>A</given-names></name><name><surname>Piomelli</surname><given-names>D</given-names></name><name><surname>Davison</surname><given-names>JS</given-names></name><name><surname>Marnett</surname><given-names>LJ</given-names></name><name><surname>Di Marzo</surname><given-names>V</given-names></name><name><surname>Pittman</surname><given-names>QJ</given-names></name><name><surname>Patel</surname><given-names>KD</given-names></name><name><surname>Sharkey</surname><given-names>KA</given-names></name></person-group><article-title>Identification and functional characterization of brainstem cannabinoid CB2 receptors</article-title><source>Science</source><year>2005</year><volume>310</volume><fpage>329</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">16224028</pub-id></citation></ref><ref id="R207"><label>207</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vanderschuren</surname><given-names>LJ</given-names></name><name><surname>Kalivas</surname><given-names>PW</given-names></name></person-group><article-title>Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies</article-title><source>Psychopharmacology (Berl.)</source><year>2000</year><volume>151</volume><fpage>99</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">10972458</pub-id></citation></ref><ref id="R208"><label>208</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Varma</surname><given-names>N</given-names></name><name><surname>Brager</surname><given-names>D</given-names></name><name><surname>Morishita</surname><given-names>W</given-names></name><name><surname>Lenz</surname><given-names>RA</given-names></name><name><surname>London</surname><given-names>B</given-names></name><name><surname>Alger</surname><given-names>B</given-names></name></person-group><article-title>Presynaptic factors in the regulation of DSI expression in hippocampus</article-title><source>Neuropharmacology</source><year>2002</year><volume>43</volume><fpage>550</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">12367601</pub-id></citation></ref><ref id="R209"><label>209</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Veldhuis</surname><given-names>WB</given-names></name><name><surname>van der Stelt</surname><given-names>M</given-names></name><name><surname>Wadman</surname><given-names>MW</given-names></name><name><surname>van Zadelhoff</surname><given-names>G</given-names></name><name><surname>Maccarrone</surname><given-names>M</given-names></name><name><surname>Fezza</surname><given-names>F</given-names></name><name><surname>Veldink</surname><given-names>GA</given-names></name><name><surname>Vliegenthart</surname><given-names>JF</given-names></name><name><surname>Bar</surname><given-names>PR</given-names></name><name><surname>Nicolay</surname><given-names>K</given-names></name><name><surname>Di Marzo</surname><given-names>V</given-names></name></person-group><article-title>Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat role of vanilloid receptors and lipoxygenases</article-title><source>J. Neurosci.</source><year>2003</year><volume>23</volume><fpage>4127</fpage><lpage>4133</lpage><pub-id pub-id-type="pmid">12764100</pub-id></citation></ref><ref id="R210"><label>210</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Villares</surname><given-names>J</given-names></name></person-group><article-title>Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain</article-title><source>Neuroscience</source><year>2007</year><volume>145</volume><fpage>323</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">17222515</pub-id></citation></ref><ref id="R211"><label>211</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Voruganti</surname><given-names>LN</given-names></name><name><surname>Slomka</surname><given-names>P</given-names></name><name><surname>Zabel</surname><given-names>P</given-names></name><name><surname>Mattar</surname><given-names>A</given-names></name><name><surname>Awad</surname><given-names>AG</given-names></name></person-group><article-title>Cannabis induced dopamine release: an <italic>in-vivo</italic> SPECT study</article-title><source>Psychiatry Res.</source><year>2001</year><volume>107</volume><fpage>173</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">11566433</pub-id></citation></ref><ref id="R212"><label>212</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wachtel</surname><given-names>SR</given-names></name><name><surname>ElSohly</surname><given-names>MA</given-names></name><name><surname>Ross</surname><given-names>SA</given-names></name><name><surname>Ambre</surname><given-names>J</given-names></name><name><surname>de Wit</surname><given-names>H</given-names></name></person-group><article-title>Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans</article-title><source>Psychopharmacology (Berl.)</source><year>2002</year><volume>161</volume><fpage>331</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">12073159</pub-id></citation></ref><ref id="R213"><label>213</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>JA</given-names></name><name><surname>Varga</surname><given-names>K</given-names></name><name><surname>Ellis</surname><given-names>EF</given-names></name><name><surname>Rzigalinski</surname><given-names>BA</given-names></name><name><surname>Martin</surname><given-names>BR</given-names></name><name><surname>Kunos</surname><given-names>G</given-names></name></person-group><article-title>Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock</article-title><source>Nature</source><year>1997</year><volume>390</volume><fpage>518</fpage><lpage>521</lpage><pub-id pub-id-type="pmid">9394002</pub-id></citation></ref><ref id="R214"><label>214</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wenger</surname><given-names>T</given-names></name><name><surname>Moldrich</surname><given-names>G</given-names></name><name><surname>Furst</surname><given-names>S</given-names></name></person-group><article-title>Neuromorphological background of cannabis addiction</article-title><source>Brain Res. Bull.</source><year>2003</year><volume>61</volume><fpage>125</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">12831997</pub-id></citation></ref><ref id="R215"><label>215</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>FJ</given-names></name></person-group><article-title>Synaptic regulation of mesocorticolimbic dopamine neurons</article-title><source>Annu. Rev. Neurosci.</source><year>1996</year><volume>19</volume><fpage>405</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">8833449</pub-id></citation></ref><ref id="R216"><label>216</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>RI</given-names></name><name><surname>Nicoll</surname><given-names>RA</given-names></name></person-group><article-title>Endocannabinoid signaling in the brain</article-title><source>Science</source><year>2002</year><volume>296</volume><fpage>678</fpage><lpage>682</lpage><pub-id pub-id-type="pmid">11976437</pub-id></citation></ref><ref id="R217"><label>217</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Witting</surname><given-names>A</given-names></name><name><surname>Walter</surname><given-names>L</given-names></name><name><surname>Wacker</surname><given-names>J</given-names></name><name><surname>Moller</surname><given-names>T</given-names></name><name><surname>Stella</surname><given-names>N</given-names></name></person-group><article-title>P2X7 receptors control 2-arachidonoylglycerol production by microglial cells</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>3214</fpage><lpage>3219</lpage><pub-id pub-id-type="pmid">14976257</pub-id></citation></ref><ref id="R218"><label>218</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>ME</given-names></name></person-group><article-title>Addiction: making the connection between behavioral changes and neuronal plasticity in specific pathways</article-title><source>Mol. Interv.</source><year>2002</year><volume>2</volume><fpage>146</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">14993375</pub-id></citation></ref><ref id="R219"><label>219</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yanovsky</surname><given-names>Y</given-names></name><name><surname>Mades</surname><given-names>S</given-names></name><name><surname>Misgeld</surname><given-names>U</given-names></name></person-group><article-title>Retrograde signaling changes the venue of postsynaptic inhibition in rat substantia nigra</article-title><source>Neuroscience</source><year>2003</year><volume>122</volume><fpage>317</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">14614899</pub-id></citation></ref><ref id="R220"><label>220</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zammit</surname><given-names>S</given-names></name><name><surname>Allebeck</surname><given-names>P</given-names></name><name><surname>Andreasson</surname><given-names>S</given-names></name><name><surname>Lundberg</surname><given-names>I</given-names></name><name><surname>Lewis</surname><given-names>G</given-names></name></person-group><article-title>Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study</article-title><source>BMJ</source><year>2002</year><volume>325</volume><fpage>1199</fpage><pub-id pub-id-type="pmid">12446534</pub-id></citation></ref><ref id="R221"><label>221</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>PW</given-names></name><name><surname>Ishiguro</surname><given-names>H</given-names></name><name><surname>Ohtsuki</surname><given-names>T</given-names></name><name><surname>Hess</surname><given-names>J</given-names></name><name><surname>Carillo</surname><given-names>F</given-names></name><name><surname>Walther</surname><given-names>D</given-names></name><name><surname>Onaivi</surname><given-names>ES</given-names></name><name><surname>Arinami</surname><given-names>T</given-names></name><name><surname>Uhl</surname><given-names>GR</given-names></name></person-group><article-title>Human cannabinoid receptor 1: 5' exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse</article-title><source>Mol. Psychiatry</source><year>2004</year><volume>9</volume><fpage>916</fpage><lpage>931</lpage><pub-id pub-id-type="pmid">15289816</pub-id></citation></ref><ref id="R222"><label>222</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zimmer</surname><given-names>A</given-names></name><name><surname>Zimmer</surname><given-names>AM</given-names></name><name><surname>Hohmann</surname><given-names>AG</given-names></name><name><surname>Herkenham</surname><given-names>M</given-names></name><name><surname>Bonner</surname><given-names>TI</given-names></name></person-group><article-title>Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1999</year><volume>96</volume><fpage>5780</fpage><lpage>5785</lpage><pub-id pub-id-type="pmid">10318961</pub-id></citation></ref><ref id="R223"><label>223</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zygmunt</surname><given-names>PM</given-names></name><name><surname>Petersson</surname><given-names>J</given-names></name><name><surname>Andersson</surname><given-names>DA</given-names></name><name><surname>Chuang</surname><given-names>H</given-names></name><name><surname>Sorgard</surname><given-names>M</given-names></name><name><surname>Di Marzo</surname><given-names>V</given-names></name><name><surname>Julius</surname><given-names>D</given-names></name><name><surname>Hogestatt</surname><given-names>ED</given-names></name></person-group><article-title>Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide</article-title><source>Nature</source><year>1999</year><volume>400</volume><fpage>452</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">10440374</pub-id></citation></ref></ref-list></back></article>